<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>

    <title>Pocket Medicine, 8e</title>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
  <link rel="stylesheet" type="text/css" href="../stylesheet.css"/>
<link rel="stylesheet" type="text/css" href="../page_styles.css"/>

  


<link href="../calibreHtmlOutBasicCss.css" type="text/css" rel="stylesheet" />

</head>
<body>

<div class="calibreMeta">
  <div class="calibreMetaTitle">
  
  
    
    <h1>
      <a href="../../j09u21sl.html">Pocket Medicine (Pocket Notebook Series)
</a>
    </h1>
    
    
  
  </div>
  <div class="calibreMetaAuthor">
    Marc Sabatine

  </div>
</div>

<div class="calibreMain">

  <div class="calibreEbookContent">
    
      <div class="calibreEbNavTop">
        
          <a href="part0007.html" class="calibreAPrev">previous page
</a>
        

        
          <a href="part0009.html" class="calibreANext">next page
</a>
        
      </div>
    

    
<h2 class="ct"><a id="h21" class="calibre8"></a><a id="page_2-1" class="calibre8"></a><a href="part0003.html#rh26" class="calibre8">DYSPNEA</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Pathophysiology</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Etiologies</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Airway obstruction</b> (↑ resistance to airflow)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Asthma</b>, <b class="calibre7">COPD</b>, bronchiectasis, cystic fibrosis, tumor, foreign body, vocal cord dysfunction, anaphylaxis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Alveolar / Parenchymal disease</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Pulmonary edema</b>: <i class="calibre6">cardiogenic or noncardiogenic</i></p>
<p class="tbody"><b class="calibre7">ILD; pneumonia</b>; atelectasis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Vascular</b></p>
<p class="tbody">(V/Q mismatch)</p></td>
<td class="th1"><p class="tbody">Large vessel: <b class="calibre7">PE</b>, tumor emboli</p>
<p class="tbody">Small vessel: PHT, vasculitis, ILD, emphysema, PNA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Chest wall</b></p>
<p class="tbody">(↑ resistance to expansion; weakness of respir. muscles)</p></td>
<td class="th1"><p class="tbody">Pleural disease<b class="calibre7">: large effusion</b>, fibrosis, pneumothorax</p>
<p class="tbody">Chest wall/diaphragm: kyphoscoliosis, ↑ abd girth</p>
<p class="tbody">Neuromuscular disorders (ALS, GBS, MG)</p>
<p class="tbody">Hyperinflation (COPD, asthma)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Stimulation of receptors</b></p></td>
<td class="th1"><p class="tbody">Chemoreceptors: <b class="calibre7">hypoxemia</b>, metabolic acidosis</p>
<p class="tbody">Mechanoreceptors: ILD, pulmonary edema, PHT, PE</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">↓ <b class="calibre7">O<sub class="calibre17">2</sub> carrying cap.</b> (but nl P<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub>)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Anemia</b>, methemoglobinemia, CO poisoning</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Psychological</b></p></td>
<td class="th1"><p class="tbody">Anxiety, panic attack, depression, somatization</p></td>
</tr>
</tbody>
</table>
<p class="h">Evaluation</p>
<p class="noindent1">• History: quality of sensation, tempo, positional dependence, exac./allev. factors, exertion</p>
<p class="noindent1">• Cardiopulmonary exam, S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>, CXR (see Appendix &amp; Radiology inserts), ECG, ABG, U/S Predictors of CHF: h/o CHF, PND, S<sub class="calibre10">3</sub>, CXR w/ venous congestion, AF <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2005;294:1944)</span> Dyspnea w/ nl CXR: CAD, asthma, PE, PHT, early ILD, anemia, acidosis, NM disease</p>
<p class="noindent1">• Based on results of initial evaluation: PFT, chest CT, TTE, cardiopulmonary testing</p>
<p class="noindent1">• <b class="calibre7">BNP &amp; NT-proBNP</b> ↑ in CHF (also ↑ in AF, RV strain from PE, COPD flare, PHT, ARDS) BNP &lt;100 pg/mL to r/o CHF (90% Se), &gt;400 to r/i <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;347:161)</span> NT-proBNP &lt;300 pg/mL to r/o CHF (99% Se); age-related cut points to r/i: &gt;450 pg/mL (&lt;50 y), &gt;900 (50–75 y), &gt;1800 (&gt;75 y) <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2006;27:330)</span></p>
<p class="noindent2">↑ in chronic HF, ∴ need to compare to known “dry BNP.” May be falsely low in obesity.</p>
<h2 class="ct"><a id="h22" class="calibre8"></a><a href="part0003.html#rh27" class="calibre8">PULMONARY FUNCTION TESTS (PFTs)</a></h2>
<p class="noindent1">• <b class="calibre7">Spirometry:</b> evaluate for obstructive disease</p>
<p class="noindent2">Flow-volume loops: diagnose and/or localize obstruction</p>
<p class="noindent2">Bronchodilator: indicated if obstruction at baseline or asthma clinically suspected</p>
<p class="noindent2">Methacholine challenge: helps dx asthma if spirometry nl, &gt;20% ↓ FEV<sub class="calibre10">1</sub> → asthma</p>
<p class="noindent1">• <b class="calibre7">Lung volumes:</b> evaluate for hyperinflation or restrictive disease including NM causes</p>
<p class="noindent1">• <b class="calibre7">D<sub class="calibre10">L</sub>CO:</b> evaluates functional surface area for gas exchange; helps differentiate causes of obstructive and restrictive diseases and screens for vascular disease &amp; early ILD</p>
<div class="cap">
<p class="caption"><a id="fig2-1" class="calibre4"></a><b class="calibre7">Figure 2-1</b> Approach to abnormal PFTs</p>
<p class="imagef1"><img src="../images/00038.jpeg" alt="" class="calibre5"/></p>
</div>
<h2 class="ct"><a id="h23" class="calibre8"></a><a id="page_2-2" class="calibre8"></a><a href="part0003.html#rh28" class="calibre8">ASTHMA</a></h2>
<p class="h">Definition and epidemiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;391:783)</span></p>
<p class="noindent1">• Chronic inflam disorder w/ <b class="calibre7">airway hyperresponsiveness + variable airflow obstruction</b></p>
<p class="noindent1">• Affects 5–10% population; ~85% of cases by age 40 y</p>
<p class="h">Clinical manifestations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;369:549)</span></p>
<p class="noindent1">• Classic triad =<b class="calibre7"> wheezing, cough, dyspnea;</b> others include chest tightness, sputum; symptoms typically <i class="calibre6">chronic</i> with <i class="calibre6">episodic exacerbation</i></p>
<p class="noindent1">• Precipitants <b class="calibre7">(triggers)</b></p>
<p class="noindent2"><i class="calibre6">respiratory irritants</i> (smoke, perfume, etc.) &amp; <i class="calibre6">allergens</i> (pets, dust mites, pollen, etc.)</p>
<p class="noindent2"><i class="calibre6">infections</i> (URI, bronchitis, sinusitis)</p>
<p class="noindent2"><i class="calibre6">drugs</i> (eg, ASA &amp; NSAIDs via leukotrienes, βB via bronchospasm, MSO<sub class="calibre10">4</sub> via histamine)</p>
<p class="noindent2">emotional stress, cold air, exercise (increase in ventilation dries out airways)</p>
<p class="h">Physical examination</p>
<p class="noindent1">• Wheezing and prolonged expiratory phase</p>
<p class="noindent1">• Presence of nasal polyps, rhinitis, rash → <i class="calibre6">allergic component</i></p>
<p class="noindent1">• Exacerbation → ↑ RR, ↑ HR, accessory muscle use, diaphoresis, pulsus paradoxus</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;318:279)</span></p>
<p class="noindent1">• <b class="calibre7">Spirometry:</b> ↓ FEV<sub class="calibre10">1</sub>, ↓ FEV<sub class="calibre10">1</sub>/FVC, coved flow-volume loop; lung volumes: ± ↑ RV &amp; TLC</p>
<p class="noindent2">⊕ bronchodilator response (↑ FEV<sub class="calibre10">1</sub> ≥12% &amp; ≥200 mL) strongly suggestive of asthma</p>
<p class="noindent2">methacholine challenge (↓ FEV<sub class="calibre10">1</sub> ≥20%) if PFTs nl: Se &gt;90%</p>
<p class="noindent1">• Allergy suspected → consider checking serum IgE, eos, skin testing/RAST</p>
<p class="h">Ddx <span class="r">(“all that wheezes is not asthma…”)</span></p>
<p class="noindent1">• Hyperventilation &amp; panic attacks</p>
<p class="noindent1">• Upper airway obstruction or inh foreign body; laryngeal/vocal cord dysfxn (eg, 2° to GERD)</p>
<p class="noindent1">• CHF (“cardiac asthma”); COPD; bronchiectasis; ILD (including sarcoidosis); vasculitis; PE</p>
<p class="h">“Asthma plus” syndromes</p>
<p class="noindent1">• Atopy = asthma + allergic rhinitis + atopic dermatitis</p>
<p class="noindent1">• Aspirin-exacerbated respiratory disease (Samter’s syndrome) = asthma + ASA sensitivity + nasal polyps <span class="r1">(</span><span class="r2">J Allergy Clin Immunol</span> <span class="r1">2015;135:676)</span></p>
<p class="noindent1">• ABPA = asthma + pulmonary infiltrates + hypersensitivity to <i class="calibre6">Aspergillus</i> <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2009;135:805)</span></p>
<p class="noindent2">Dx: ↑ IgE to <i class="calibre6">Asperg.</i> &amp; total (&gt;1000), ↑ <i class="calibre6">Asperg.</i> IgG levels, ↑ eos, central bronchiectasis</p>
<p class="noindent2">Rx: steroids ± itra-/voriconazole for refractory cases <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2000;342:756)</span></p>
<p class="noindent1">• Eosinophilic granulomatosis w/ polyangiitis (EGPA, previously Churg-Strauss) = asthma + eosinophilia + granulomatous vasculitis</p>
<p class="h1cr">C<small class="calibre31">HRONIC</small> M<small class="calibre31">ANAGEMENT</small></p>
<p class="h">“Reliever” medications <span class="r">(used prn to quickly relieve sx)</span></p>
<p class="noindent1">• Low-dose inhaled <b class="calibre7">corticosteroids</b> (ICS) +<i class="calibre6"> long-acting</i> inh <b class="calibre7">β<sub class="calibre10">2</sub>-agonists</b> (LABA): budesonide-formoterol <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2020)</span></p>
<p class="noindent1">• <i class="calibre6">Short-acting</i> inh <b class="calibre7">β<sub class="calibre10">2</sub>-agonists</b> (SABA): albuterol Rx of choice</p>
<p class="noindent1">• <i class="calibre6">Short-acting</i> inh <b class="calibre7">anticholinergics</b> (ipratropium) ↑ β<sub class="calibre10">2</sub>-agonist delivery → ↑ bronchodilation</p>
<p class="h">“Controller” meds <span class="r">(taken daily to keep control)</span> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020;324:2301)</span></p>
<p class="noindent1">• <b class="calibre7">ICS</b> Rx of choice. Superior to LAMA if sputum w/ ≥2% eos <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:2009)</span>. PO steroids may be needed for severely uncontrolled asthma; avoid if possible b/c of systemic side effects.</p>
<p class="noindent1">• LABA (eg, salmeterol, formoterol) safe &amp; ↓ exacerb. when added to ICS <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:2497)</span></p>
<p class="noindent1">• <i class="calibre6">Long-acting</i> inh <b class="calibre7">antimuscarinics</b> (LAMA; eg, tiotropium, umeclidinium): may consider if sx despite ICS+LABA <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2018;319:1473)</span></p>
<p class="noindent1">• <b class="calibre7">Leukotriene receptor antagonists</b> (LTRA): some Pts very responsive, esp. ASA-sens and exercise-induced. Warning for serious neuropsychiatric effects, including suicide.</p>
<p class="noindent1">• <b class="calibre7">Nedocromil/cromolyn:</b> limited use in adults. Useful in young Pts, exercise-induced bronchospasm; ineffective unless used before trigger or exercise exposure.</p>
<p class="h">Immunotherapies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:965)</span></p>
<p class="noindent1">• Allergen ImmunoRx (“allergy shots”) may help if sig. allerg. component <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:1715)</span></p>
<p class="noindent1">• Anti-IgE (omalizumab) for uncontrolled mod-to-severe allergic asthma (w/ IgE &gt;30) on ICS ± LABA <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017; 318:279)</span>; ↓ exacerbations in severe asthma <span class="r1">(</span><span class="r2">Cochrane</span> <span class="r1">2014;CD003559)</span></p>
<p class="noindent1">• Anti-IL5 (mepolizumab, reslizumab) ↓ exacerb in severe asthma <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;371:1189 &amp; 1198)</span></p>
<p class="noindent1">• Anti-IL5Rα (benralizumab) ↓ steroid use, ↓ exac. in sev asthma w/ eos <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:2448)</span></p>
<p class="noindent1">• Anti-IL4Rα (dupilumab) blocks IL-4 &amp; IL-13; ↓ exacerb in severe asthma, ↓ steroid use, ↑ FEV<sub class="calibre10">1</sub> <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:2475 &amp; 2486)</span></p>
<p class="noindent1">• Anti-TSLP (tezepelumab-ekko) ↓ exacerbations in severe asthma; can use in non-allergic/non-eosinophilic asthma <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:1800)</span></p>
<p class="h"><a id="page_2-3" class="calibre4"></a>Principles of treatment</p>
<p class="noindent1">• Education and avoidance of environmental triggers <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;386:1075)</span>; yearly flu shot</p>
<p class="noindent1">• Use quick-relief rescue medication as needed for all Pts</p>
<p class="noindent1">• Goal to achieve <b class="calibre7">complete control</b> = daily sx ≤2/wk, Ø nocturnal sx or limitation of activity, reliever med ≤2/wk, nl peak expiratory flow rate or FEV<sub class="calibre10">1</sub>; partly controlled = 1–2 of the above present in a wk; uncontrolled = ≥3 of the above present in a wk</p>
<p class="noindent1">• Step up treatment as needed to gain control, step down as tolerated</p>
<p class="noindent1">• Can abort exacerb by quadrupling ICS if deteriorating control <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:902)</span></p>
<p class="imaget"><img src="../images/00039.jpeg" alt="" class="calibre5"/></p>
<p class="tfn">Category for sx determined by most severe day or nocturnal element</p>
<p class="h1cr">E<small class="calibre31">XACERBATION</small></p>
<p class="h">Evaluation</p>
<p class="noindent1">• History: baseline PEF, steroid requirement, ED visits, hospital admissions, prior intubation</p>
<p class="noindent2">Current exacerbation: duration, severity, potential precipitants, meds used</p>
<p class="noindent2"><i class="calibre6">Risk factors for life-threatening:</i> prior intubation, h/o near-fatal asthma, ED visit/hosp for asthma w/in 1 y, current/recent PO steroids, not using ICS, overdependent on SABA, Ψ, h/o noncompliance</p>
<p class="noindent1">• Physical exam: VS, pulm, accessory muscle use, pulsus paradoxus, abdominal paradox</p>
<p class="noindent2">Assess for barotrauma: asymmetric breath sounds, tracheal deviation, subcutaneous air → pneumothorax, precordial (Hamman’s) crunch → pneumomediastinum</p>
<p class="noindent1">• Diagnostic studies: <b class="calibre7">peak expiratory flow</b> (know personal best; &lt;80% personal best c/w poor control, &lt;50% c/w severe exacerbation); <b class="calibre7">S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>; CXR</b> to r/o PNA or PTX;  ABG if severe (low P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> initially; nl or high P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> <i class="calibre6">may</i> signify tiring)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre25"/>
<col class="calibre20"/>
<col class="calibre20"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Severity of Asthma Exacerbation</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Mild-Moderate</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Severe</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Life-Threatening</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Symptoms</p></td>
<td class="th1"><p class="tbodyc">Talks in phrases</p></td>
<td class="th1"><p class="tbodyc">Talks in words, tripod positioning</p></td>
<td class="th1"><p class="tbodyc">Drowsy</p>
<p class="tbodyc">Confused</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Vitals/ Exam</p></td>
<td class="th1"><p class="tbodyc">RR &gt;20, HR 100–120, Room air S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub> 90–95%</p></td>
<td class="th1"><p class="tbodyc">RR &gt;30, HR &gt;120</p>
<p class="tbodyc">Room air S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub> &lt;90%</p></td>
<td class="th1"><p class="tbodyc">Silent chest</p>
<p class="tbodyc">Bradycardia</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">PEF</p></td>
<td class="th1"><p class="tbodyc">&gt;50% predicted or best</p></td>
<td class="th1"><p class="tbodyc">≤50% predicted or best</p></td>
<td class="th1"><p class="tbodyc">Not indicated</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Initial Treatment</p></td>
<td class="th1"><p class="tbodyc">O<sub class="calibre17">2</sub>, SABA 4–10 puffs q20min, prednisone</p></td>
<td class="th1"><p class="tbodyc">Tx to acute facility,</p>
<p class="tbodyc">SABA, ipratropium, methylpred, IV Mg</p></td>
<td class="th1"><p class="tbodyc">Tx to acute facility, prepare for intubation</p>
<p class="tbodyc">SABA, ipratropium, methylpred, IV Mg</p></td>
</tr>
</tbody>
</table>
<p class="h">Initial treatment details <span class="r">(GINA 2021 Guidelines)</span></p>
<p class="noindent1">• <b class="calibre7">Oxygen</b> to keep S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> ≥93–95%</p>
<p class="noindent1">• <b class="calibre7">Inhaled SABA</b> (eg, albuterol) by MDI (4–8 puffs) or nebulizer (2.5–5 mg) q20min</p>
<p class="noindent1">• <b class="calibre7">Corticosteroids:</b> prednisone 40–60 mg PO if outPt; methylpred IV if ED or inPt</p>
<p class="noindent1">• <b class="calibre7">Ipratropium</b> MDI (4–6 puffs) or nebulizer (0.5 mg) q20min if severe <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2002;121:1977)</span></p>
<p class="noindent1">• <i class="calibre6">Reassess after 60–90 min of Rx</i></p>
<p class="noindent2">Mild–mod exacerbation: cont SABA q1h</p>
<p class="noindent2">Sev exacerbation: SABA &amp; ipratropium q1h or cont.; if refractory, consider Mg ± heliox</p>
<p class="noindent1">• <i class="calibre6">Decide disposition within 4 h of presentation and after 1–3 h of Rx</i></p>
<p class="noindent1">• <b class="calibre7">High-dose steroids:</b> methylpred 125 mg IV q6h <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1999;340:1941)</span></p>
<div class="cap">
<p class="caption"><a id="page_2-4" class="calibre4"></a><a id="fig2-2" class="calibre4"></a><b class="calibre7">Figure 2-2</b> Disposition of patients after initial treatment of asthma exacerbation</p>
<p class="imagef1"><img src="../images/00040.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">ICU-level care</p>
<p class="noindent1">• <b class="calibre7">Invasive ventilation:</b></p>
<p class="noindent2">Large ET tube, P<sub class="calibre10">plat</sub> &lt;30 cm H<sub class="calibre10">2</sub>O (predicts barotrauma better than PIP), max exp time</p>
<p class="noindent2">PEEP individualized to patient physiology</p>
<p class="noindent2">Paralysis, inhalational anesthetics, bronchoalveolar lavage w/ mucolytic, heliox (60–80% helium) and ECMO have been used with success</p>
<p class="noindent2">IV ketamine: bronchodilating effects and can be used for refractory status asthmaticus</p>
<p class="noindent1">• NPPV likely improves obstruction <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2003;123:1018)</span>, but controversial and rarely used</p>
<h2 class="ct"><a id="h24" class="calibre8"></a><a href="part0003.html#rh29" class="calibre8">ANAPHYLAXIS</a></h2>
<p class="h">Definition and pathophysiology <span class="r1">(</span><span class="r2">Ann Emerg Med 2006;47:373</span><span class="r1">)</span></p>
<p class="noindent1">• Severe, rapid onset (mins to hrs), potentially life-threatening systemic allergic response</p>
<p class="noindent1">• IgE-mediated mast cell degranulation with release of histamine, tryptase, and TNF</p>
<p class="noindent1">• Precipitates systemic reactions (bronchospasm, tissue swelling, fluid shifts, vasodilation)</p>
<p class="noindent1">• Common triggers: penicillins, cephalosporins, shellfish, nuts, insect stings, IV contrast (not truly an IgE-mediated mechanism, but clinically similar)</p>
<p class="h">Diagnosis: <span class="r">any of the three following criteria</span></p>
<p class="noindent1">1) Acute illness with skin ± mucosal involvement (rash, flushing, hives), AND at least one of:</p>
<p class="noindent2">Respiratory compromise (wheeze, stridor, dyspnea, hypoxemia)</p>
<p class="noindent2">Hypotension or hypoperfusion (syncope, incontinence)</p>
<p class="noindent1">2) Two or more of the following after exposure to a <b class="calibre7">likely</b> allergen: skin/mucosal involvement, respiratory compromise, ↓ BP or hypoperfusion, GI symptoms</p>
<p class="noindent1">3) Hypotension after exposure to <b class="calibre7">known</b> allergen for that Pt</p>
<p class="h">Treatment</p>
<p class="noindent1">• <b class="calibre7">Epi:</b> 0.5 mg IM (0.5 mL of 1 mg/mL solution) q5–15min as needed. For those who do not respond, IV infusion starting at 0.1 mcg/kg/min.</p>
<p class="noindent1">• <b class="calibre7">Airway:</b> suppl O<sub class="calibre10">2</sub> ± intubation or cricothyroidotomy (if laryngeal edema); β<sub class="calibre10">2</sub>-agonists</p>
<p class="noindent1">• Fluid resuscitation w/ ≥1–2 L crystalloid (may extravasate up to 35% of intravasc volume)</p>
<p class="noindent1">• Antihistamines relieve hives &amp; itching, <i class="calibre6">no effect on airway or hemodynamics;</i> H1RA (diphenhydramine 50 mg IV/IM)</p>
<p class="noindent1">• Methylprednisolone 1–2 mg/kg/d × 1–2 d for those who do not respond to epi</p>
<p class="noindent1">• Avoid unopposed α-adrenergic vasopressors</p>
<p class="h">Disposition</p>
<p class="noindent1">• Mild rxn limited to urticaria or mild bronchospasm can be observed for ≥6 h; admit all others</p>
<p class="noindent1">• Watch for <b class="calibre7">biphasic reaction;</b> occurs in 23%, typically w/in 8–10 h but up to 72 h</p>
<p class="h">Angioedema <span class="r1">(</span><span class="r2">J Allergy Clin Immunol</span> <span class="r1">2013;131:1491)</span></p>
<p class="noindent1">• Localized swelling of skin/mucosa; involves face, lips, tongue, uvula, larynx, and bowels</p>
<p class="noindent1">• Etiologies: mast cell-mediated (eg, NSAIDs); bradykinin-mediated (eg, <b class="calibre7">ACEI,</b> ARNi, hereditary angioedema, acquired C1 inhibitor deficiency); idiopathic</p>
<p class="noindent1">• Diagnosis: C4 and C1 inhibitor level, tryptase (if suspect anaphylaxis), ESR/CRP</p>
<p class="noindent1">• Rx: intubation if risk of airway compromise. Allergic angioedema: H1/H2 antihist., steroids.</p>
<p class="noindent2">If 2° ACEI: d/c ACEI, antihist., icatibant (bradykinin-receptor antag; <span class="r2">NEJM</span> <span class="r1">2015;372:418</span>).</p>
<p class="noindent2">Hereditary angioedema: plasma-derived C1 inhibitor, ecallantide (kallikrein inhibitor)</p>
<h2 class="ct"><a id="h25" class="calibre8"></a><a id="page_2-5" class="calibre8"></a><a href="part0003.html#rh30" class="calibre8">CHRONIC OBSTRUCTIVE PULMONARY DISEASE</a></h2>
<p class="h">Definition and epidemiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:1931)</span></p>
<p class="noindent1">• Progressive airflow limitation caused by airway and parenchymal inflammation</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Emphysema vs. Chronic Bronchitis</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"> </p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Emphysema</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Chronic Bronchitis</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Definition</b></p></td>
<td class="th1"><p class="tbody">Dilation/destruction of parenchyma (path definition)</p></td>
<td class="th1"><p class="tbody">Productive cough &gt;3 mo/y × ≥2 y (clinical definition)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pathophysiology</b></p></td>
<td class="th1"><p class="tbody">Tissue destruction</p>
<p class="tbody">V/Q: ↑ dead space fraction → hypercarbia, but only mild hypoxemia</p></td>
<td class="th1"><p class="tbody">Small airways affected</p>
<p class="tbody">V/Q: ↑ shunt fraction → severe hypoxemia, hypercapnia PHT, cor pulmonale</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Clinical manifestations</b></p></td>
<td class="th1"><p class="tbody">Severe, constant dyspnea</p>
<p class="tbody">Mild cough</p></td>
<td class="th1"><p class="tbody">Intermittent dyspnea</p>
<p class="tbody">Copious sputum production</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Physical exam</b></p></td>
<td class="th1"><p class="tbody">“Pink puffer”</p>
<p class="tbody">Tachypneic, noncyanotic, thin</p>
<p class="tbody">Diminished breath sounds</p></td>
<td class="th1"><p class="tbody">“Blue bloater”</p>
<p class="tbody">Cyanotic, obese, edematous</p>
<p class="tbody">Rhonchi &amp; wheezes</p></td>
</tr>
</tbody>
</table>
<p class="h">Pathogenesis <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2017;389:1931)</span></p>
<p class="noindent1">• <b class="calibre7">Cigarette smoke</b> (centrilobular emphysema, affects 15–20% of smokers)</p>
<p class="noindent1">• Recurrent airway infections</p>
<p class="noindent1">• α<sub class="calibre10">1</sub>-antitrypsin deficiency: early-onset panacinar emphysema or signif basilar disease, 1–3% of COPD cases. Suspect if age &lt;45, lower lungs affected, extrathoracic manifestations (liver disease [not if heterozygote MZ], FMD, pancreatitis). ✓ serum A1AT level (nb, acute phase reactant).</p>
<p class="noindent1">• Low FEV<sub class="calibre10">1</sub> in early adulthood associated w/ COPD <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:111)</span></p>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Chronic cough, sputum production, dyspnea; later stages → freq exacerb, AM HA, wt loss</p>
<p class="noindent1">• Exacerbation triggers: infection, other cardiopulmonary disease, including PE</p>
<p class="noindent2">Infxn: overt tracheobronchitis/pneumonia from viruses, <i class="calibre6">S. pneumoniae, H. influenzae,</i> <i class="calibre6">M. catarrhalis</i> or triggered by changes in strain of colonizers <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2008;359:2355)</span></p>
<p class="noindent1">• Physical exam: ↑ AP diameter of chest (“barrel chest”), hyperresonance, ↓ diaphragmatic excursion, ↓ breath sounds, ↑ expiratory phase, rhonchi, wheezes during exacerbation: tachypnea, accessory muscle use, pulsus paradoxus, cyanosis</p>
<p class="noindent1">• <i class="calibre6">Asthma-COPD overlap syndrome</i> (ACOS; <span class="r2">NEJM</span> <span class="r1">2015;373:1241</span>): features of both present. For example: reversibility of airway obstruction w/ bronchodilator in COPD; neutrophilic inflammation in asthma (more classic in COPD); eos in COPD.</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;321:786)</span></p>
<p class="noindent1">• CXR (see Radiology inserts): hyperinflation, flat diaphragms, ± interstitial markings &amp; bullae</p>
<p class="noindent1">• PFTs: <b class="calibre7">obstruction:</b> ↓↓ FEV<sub class="calibre10">1</sub>, ↓ <b class="calibre7">FVC, FEV</b><sub class="calibre10">1</sub><b class="calibre7">/FVC</b> &lt;<b class="calibre7">0.7 (no sig</b> Δ<b class="calibre7"> post bronchodilator),</b> expiratory coving of flow-volume loop; <b class="calibre7">hyperinflation:</b> ↑↑ RV, ↑ TLC, ↑ RV/TLC; <b class="calibre7">abnormal gas exchange:</b> ↓ D<sub class="calibre10">L</sub>CO (in emphysema)</p>
<p class="noindent1">• ABG: ↓ P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>, ± ↑ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> (in chronic bronchitis, usually only if FEV<sub class="calibre10">1</sub> &lt;1.5 L) and ↓ pH</p>
<p class="noindent1">• Screen <i class="calibre6">symptomatic</i> Pts w/ spirometry; don’t screen if asx; screen for α1-AT deficiency</p>
<p class="h">Chronic treatment <span class="r">(Adapted from GOLD 2021 Report)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">COPD Staging and Recommended Therapies by GOLD Criteria</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Exacerbations/Yr</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Mild Symptoms</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Mod/Severe Symptoms</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">&lt;2</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7"><span class="underline">A</span></b> Short-acting inh dilator prn</p></td>
<td class="th1"><p class="tbody"><b class="calibre7"><span class="underline">B</span></b> LAMA</p></td>
</tr>
<tr class="calibre15">
<td rowspan="2" class="th1"><p class="tbodyc"><b class="calibre7">≥2</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7"><span class="underline">C</span></b> LAMA</p></td>
<td class="th1"><p class="tbody"><b class="calibre7"><span class="underline">D</span></b> LAMA + LABA ± ICS</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody">Consider adding PDE-4 inhib to bronchodilator</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Smoking cessation &amp; vaccinations in all. Pulm rehab in groups B–D. O<sub class="calibre24">2</sub> as indicated per S<sub class="calibre24">a</sub>O<sub class="calibre24">2</sub>.</p>
<p class="noindent1">• <b class="calibre7">Bronchodilators</b> (<i class="calibre6">1<sup class="calibre19">st</sup>-line</i>)<b class="calibre7">: long-acting muscarinic antag (LAMA),</b> β<sub class="calibre10">2</sub>-agonists (LABA)</p>
<p class="noindent2">LAMA (eg, tiotropium): ↓ exacerb, slows ↓ FEV<sub class="calibre10">1</sub>, ↓ admit, ↓ resp failure; better than ipratropium or LABA <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2008;359:1543; 2011;364:1093; 2017;377:923)</span></p>
<p class="noindent2">LABA: ~11% ↓ in exacerbations, no ↑ in CV events <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:1817)</span></p>
<p class="noindent2">LAMA + LABA: ↑ FEV<sub class="calibre10">1</sub>, ↓ sx vs. either alone <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2014;145:981)</span> and superior to LABA + inh steroid <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;374:2222)</span></p>
<p class="noindent1">• <b class="calibre7">Corticosteroids</b> (inhaled, ICS): ~11% ↓ in exacerbations &amp; slows ↓ FEV<sub class="calibre10">1</sub>; no Δ in mortality <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;387:1817)</span>. Greatest benefit if eos &gt;300 <span class="r1">(</span><span class="r2">Lancet Repir Med</span> <span class="r1">2018;6:117)</span>.</p>
<p class="noindent1">• “Triple Therapy” (LAMA+LABA+ICS) ↓ exac, ↓ hosp, ↑ PNA <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:35)</span></p>
<p class="noindent1">• Roflumilast (PDE-4 inhib) + bronchodil: ↑ FEV<sub class="calibre10">1</sub>, ↓ exacerb in Pts with severe COPD, chronic bronchitis, and a hx of exacerbations <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2015;385:857)</span></p>
<p class="noindent1"><a id="page_2-6" class="calibre4"></a>• Anti-IL5 (eg, mepolizumab, benralizumab): mixed data on ↓ exacerb in Pts w/ eos <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;377:1613 &amp; 2019;381:1023)</span></p>
<p class="noindent1">• Antibiotics: daily azithro ↓ exacerbations, but not routine <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;311:2225)</span></p>
<p class="noindent1">• <b class="calibre7">Oxygen:</b> if P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> ≤55 mmHg or S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> ≤89% (during rest, exercise, or sleep) to prevent cor pulmonale; only Rx proven to ↓ mortality <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">1980;93:391;</span> <span class="r2">Lancet</span> <span class="r1">1981;i:681)</span>; no benefit in Pts w/ moderate hypoxemia (S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> 89–93%) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2016;375:1617)</span> or nocturnal O<sub class="calibre10">2</sub> alone <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2020;383:1129)</span>; unknown benefit of isolated exertional O<sub class="calibre10">2</sub> <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2020;202:121)</span>.</p>
<p class="noindent1">• Night NPPV if recent exacerb &amp; P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> &gt;53 ↓ risk of readmit or death <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;317:2177)</span></p>
<p class="noindent1">• <b class="calibre7">Prevention:</b> Flu/Pneumovax; smoking cessation → 50% ↓ in lung function decline <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2002;166:675)</span> and ↓ long-term mortality <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2005;142:223)</span></p>
<p class="noindent1">• Rehabilitation: ↓ dyspnea and fatigue, ↑ exercise tolerance, ↑ QoL <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2009;360:1329)</span></p>
<p class="noindent1">• Surgery &amp; bronchoscopic interventions</p>
<p class="noindent2">Lung volume reduction surgery: ↑ exercise capacity, ↓ mortality <i class="calibre6">if</i> FEV<sub class="calibre10">1</sub> &gt;20%, upper lobe, low exercise capacity <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;348:2059)</span></p>
<p class="noindent2">Bronchoscopic lung reduction w/ endobronchial valves or coils: ↑ lung fxn but significant complications (PTX, PNA) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:2325;</span> <span class="r2">Lancet</span> <span class="r1">2015;386:1066;</span> <span class="r2">JAMA</span> <span class="r1">2016;315:175)</span></p>
<p class="noindent1">• Lung transplant: ↑ QoL and ↓ sx <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">1998;351:24)</span>, ? survival benefit <span class="r1">(</span><span class="r2">Am J Transplant</span> <span class="r1">2009;9:1640)</span></p>
<p class="h">Staging and prognosis</p>
<p class="noindent1">• Assess breathlessness, cough, sputum, exercise capacity &amp; energy (tools such as CAT and mMRC may be used as part of assessment)</p>
<p class="noindent1">• Ratio of diam PA/aorta &gt;1 associated with ~3× ↑ risk of exacerbations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:913)</span></p>
<p class="noindent1">• FEV<sub class="calibre10">1</sub> stages: I = ≥80%; II = 50–79% (~11% 3-y mort.); III = 30–49% (~15% 3-y mort.); IV = &lt;30% (~24% 3-y mort.)</p>
<p class="h1cr">E<small class="calibre31">XACERBATION</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre34"/>
<col class="calibre33"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">COPD Exacerbation Treatment</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Agent</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Dose</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ipratropium</b></p></td>
<td class="th1"><p class="tbodyh">MDI 4–8 puffs q1–2h <i class="calibre6">or</i></p>
<p class="tbodyh">Nebulizer 0.5 mg q1–2h</p></td>
<td class="th1"><p class="tbody">First-line therapy <span class="sm">(<i class="calibre6">NEJM</i> 2011;364:1093)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Albuterol</b></p></td>
<td class="th1"><p class="tbodyh">MDI 4–8 puffs q1–2h <i class="calibre6">or</i></p>
<p class="tbodyh">Nebulizer 2.5–5 mg q1–2h</p></td>
<td class="th1"><p class="tbody">Benefit if component of reversible bronchoconstriction</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Corticosteroids</b></p></td>
<td class="th1"><p class="tbodyh">Prednisone 40 mg/d × 5d <span class="sm">(<i class="calibre6">JAMA</i> 2013;309:2223)</span>; some Pts will benefit from higher dose/longer course if severe</p>
<p class="tbodyh">Methylprednisolone 125 mg IV q6h × 72 h for more severe exacerbations</p></td>
<td class="th1"><p class="tbodyh">↓ treatment failure, ↓ hosp. stay</p>
<p class="tbodyh">↑ FEV<sub class="calibre17">1</sub> but no mortality benefit,</p>
<p class="tbodyh">↑ complications <span class="sm">(<i class="calibre6">Cochrane</i> 2009:CD001288)</span></p>
<p class="tbodyh">OutPt Rx after ED visit ↓ relapse <span class="sm">(<i class="calibre6">NEJM</i> 2003;348:2618)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Antibiotics</b></p></td>
<td class="th1"><p class="tbodyh">Amox, TMP-SMX, doxy, azithro, antipneumococcal FQ all reasonable (no single abx proven superior). Consider local flora and avoid repeat courses of same abx. ≤5d course likely enough for mild–mod exacerbation <span class="sm">(<i class="calibre6">JAMA</i> 2010;303:2035)</span>.</p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">H. flu, M. catarrhalis, S. pneumo</i></p>
<p class="tbodyh">↑ PEF, ↓ Rx failure, ? ↓ short-term mort, ↓ subseq exacerb <span class="sm">(<i class="calibre6">Chest</i> 2008;133:756 &amp; 2013;143:82)</span></p>
<p class="tbodyh">Consider if CRP &gt;20 + ↑ sputum purulence or CRP &gt;40 <span class="sm">(<i class="calibre6">NEJM</i> 2019;381:111)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Oxygenation</b></p></td>
<td class="th1"><p class="tbodyh">↑ F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> to achieve P<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub> ≥55–60 <i class="calibre6">or</i> S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub> 88–92%</p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Watch for CO<sub class="calibre17">2</sub> retention</b> (due to ↑ V/Q mismatch, loss of hypoxemic resp drive, Haldane effect)<i class="calibre6">, but must maintain acceptable S<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub>!</i></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Noninvasive positive-pressure ventilation</b></p></td>
<td class="th1" colspan="2"><p class="tbodyh">Initiate <i class="calibre6">early</i> if moderate/severe dyspnea, ↓ pH / ↑ P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub>, RR &gt;25</p>
<p class="tbodyh">Results in 58% ↓ intubation, ↓ LOS by 3.2 d, 59% ↓ mortality</p>
<p class="tbodyh">Contraindications: Δ MS, inability to cooperate or clear secretions, hemodynamic instability, UGIB</p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">NEJM</i> 1995;333:817;</span> <span class="sm"><i class="calibre6">Annals</i> 2003;138:861; <i class="calibre6">Cochrane</i> 2004;CD004104; <i class="calibre6">ERJ</i> 2005;25:348)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Endotracheal intubation</b></p></td>
<td class="th1" colspan="2"><p class="tbody">Consider if P<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub> &lt;55–60, ↑’ing P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub>, ↓’ing pH, ↑ RR, respiratory</p>
<p class="tbody">fatigue, Δ MS or hemodynamic instability</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Other measures</b></p></td>
<td class="th1" colspan="2"><p class="tbody">Mucolytics overall not supported by data <span class="sm">(<i class="calibre6">Chest</i> 2001;119:1190)</span></p>
<p class="tbody">Monitor for cardiac arrhythmias</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Post-exacerb care</b></p></td>
<td class="th1" colspan="2"><p class="tbody">Follow up w/in 1 mo; smoking cessation if current smoker; vaccinations (influenza, pneumococcal), referral to pulm rehab <span class="sm">(<i class="calibre6">AJRCCM</i> 2007;176:532)</span></p></td>
</tr>
</tbody>
</table>
<h2 class="ct"><a id="h26" class="calibre8"></a><a id="page_2-7" class="calibre8"></a><a href="part0003.html#rh31" class="calibre8">SOLITARY PULMONARY NODULE</a></h2>
<p class="h">Principles</p>
<p class="noindent1">• Definition: single, well-defined, &lt;3 cm, surrounded by nl lung, no LAN or pleural effusion</p>
<p class="noindent1">• Often “incidentalomas,” esp with ↑ CT use, but may still be early, curable malignancy</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Benign (70%)</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Malignant (30%)</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Granuloma</b> (80%): TB, histo, coccidio</p>
<p class="tbody"><b class="calibre7">Hamartoma</b> (10%)</p>
<p class="tbody">Bronchogenic cyst, AVM, pulm infarct</p>
<p class="tbody">Echinococcosis, ascariasis, aspergilloma</p>
<p class="tbody">GPA, rheumatoid nodule, sarcoidosis</p>
<p class="tbody">Lipoma, fibroma, amyloidoma</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Bronchogenic carcinoma</b> (75%) periph: adeno (most common) &amp; large cell central: squamous &amp; small cell</p>
<p class="tbody"><b class="calibre7">Metastatic</b> (20%): sarcoma, melanoma, breast, head &amp; neck, colon, testicular, renal</p>
<p class="tbody">Carcinoid, primary sarcoma</p></td>
</tr>
</tbody>
</table>
<p class="h">Initial evaluation</p>
<p class="noindent1">• <b class="calibre7">History:</b> h/o cancer, smoking, age (&lt;30 y = 2% malignant, +15% each decade &gt;30)</p>
<p class="noindent1">• <b class="calibre7">CT:</b> size/shape, Ca<sup class="calibre19">2+</sup>, LAN, effusions, bony destruction, <b class="calibre7">compare w/ old studies</b></p>
<p class="noindent2">Ø Ca → ↑ likelihood malignant; laminated → granuloma; “popcorn” → hamartoma</p>
<p class="noindent1">• High-risk features for malig: size (eg, ≥2.3 cm diameter), spiculated, upper lobe, ♀, &gt;60 yo, &gt;1 ppd current smoker, no prior smoking cessation <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;348:2535 &amp; 2013;369:910)</span></p>
<p class="h">Diagnostic studies</p>
<p class="noindent1">• <b class="calibre7">PET:</b> detects metab. activity of tumors, 97% Se &amp; 78% Sp for malig (esp if &gt;8 mm). Useful for deciding which lesions to bx vs. serial CT &amp; for surgical staging b/c may detect mets.</p>
<p class="noindent1">• <b class="calibre7">Transthoracic needle biopsy</b> (TTNB): if tech feasible, 97% will obtain definitive tissue dx</p>
<p class="noindent1">• <b class="calibre7">Video-assisted thoracoscopic surgery</b> (VATS): for percutaneously inaccessible lesions; highly sensitive and allows resection</p>
<p class="noindent1">• <b class="calibre7">Transbronchial bx</b> (TBB): most lesions too small to sample w/o endobronchial U/S; bronch w/ brushings low-yield unless invading bronchus; navigational bronch 70% yield</p>
<p class="noindent1">• PPD, fungal serologies, ANCA</p>
<p class="h">Management <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2022;327:264)</span></p>
<p class="noindent1">• <b class="calibre7">Low risk</b> (&lt;5%): serial CT (freq depending on risk); shared decision w/ Pt re: bx</p>
<p class="noindent1">• <b class="calibre7">High risk</b> (and surgical candidate): TBB, TTNB, or VATS → lobectomy if malignant</p>
<p class="noindent1">• <b class="calibre7">Subsolid nodules:</b> longer f/u (b/c if malignant can be slow-growing) &amp; PET</p>
<p class="imaget"><img src="../images/00041.jpeg" alt="" class="calibre5"/></p>
<h2 class="ct"><a id="h27" class="calibre8"></a><a href="part0003.html#rh32" class="calibre8">HEMOPTYSIS</a></h2>
<p class="h">Definition and pathophysiology</p>
<p class="noindent1">• Expectoration of blood or blood-streaked sputum</p>
<p class="noindent1">• <b class="calibre7">Massive hemoptysis:</b> &gt;100 mL/h or &gt;500 mL in 24 h; massive hemoptysis usually from tortuous or invaded bronchial arteries</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies</b> <span class="sm">(<i class="calibre6">Crit Care Med</i> 2000;28:1642)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Infection/Inflammation</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Bronchitis</b> (most common cause of trivial hemoptysis)</p>
<p class="tbody"><b class="calibre7">Bronchiectasis</b> incl <b class="calibre7">CF</b> (common cause of massive hemoptysis)</p>
<p class="tbody">TB or aspergilloma (can be massive); pneumonia or lung abscess</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Neoplasm</b></p></td>
<td class="th1"><p class="tbody">Usually primary <b class="calibre7">lung cancer</b>, sometimes metastasis (can be massive)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cardiovasc</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">PE</b> (can be massive), pulmonary artery rupture (2° to instrumentation), CHF, mitral stenosis, trauma/foreign body, bronchovascular fistula</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Other</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Vasculitis</b> (GPA, anti-GBM, Behçet’s, SLE), AVM, anticoag (w/underlying lung disease), coagulopathy, cocaine, pulm hemosiderosis</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic workup</p>
<p class="noindent1">• Localize bleeding site (r/o <i class="calibre6">GI or ENT source</i> by H&amp;P ± endo); determine whether <b class="calibre7">unilateral or bilateral, localized or diffuse, parenchymal or airway</b> by CXR/chest CT ± bronch</p>
<p class="noindent1">• PT, PTT, CBC to rule out <b class="calibre7">coagulopathy</b></p>
<p class="noindent1">• Sputum culture/stain for bacteria, fungi and AFB; cytology to <b class="calibre7">r/o malignancy</b></p>
<p class="noindent1">• ANCA, anti-GBM, ANA, urinalysis to ✓ for <b class="calibre7">vasculitis</b> or <b class="calibre7">pulmonary-renal syndrome</b></p>
<p class="h"><a id="page_2-8" class="calibre4"></a>Treatment</p>
<p class="noindent1">• <b class="calibre7">Death is from asphyxiation not exsanguination</b>; maintain gas exchange, reverse coagulopathy and Rx underlying condition; cough suppressant may ↑ risk of asphyxiation</p>
<p class="noindent1">• Inhaled tranexamic acid promising <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2018;154:1379)</span></p>
<p class="noindent1">• Massive hemoptysis: <b class="calibre7">put bleeding side dependent;</b> selectively intubate nl lung if needed</p>
<p class="noindent2"><i class="calibre6">Angiography:</i> Dx &amp; Rx (vascular occlusion balloons or <b class="calibre7">selective embol of bronchial art</b>)</p>
<p class="noindent2"><i class="calibre6">Rigid bronch:</i> allows more options (electrocautery, laser) than flexible bronch</p>
<p class="noindent2"><i class="calibre6">Surgical resection</i></p>
<h2 class="ct"><a id="h28" class="calibre8"></a><a href="part0003.html#rh33" class="calibre8">BRONCHIECTASIS</a></h2>
<p class="h">Definition and epidemiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;346:1383)</span></p>
<p class="noindent1">• Obstructive airways disease of bronchi and bronchioles, chronic transmural inflammation w/ airway dilatation and thickening, collapsibility, mucus plugging w/ impaired clearance</p>
<p class="h">Initial workup</p>
<p class="noindent1">• H&amp;P: cough, dyspnea, copious sputum production, ±hemoptysis, inspiratory “squeaks”</p>
<p class="noindent1">• CXR: scattered or focal; rings of bronchial cuffing; “tram track” of dilated, thick airways</p>
<p class="noindent1">• PFTs: obstructive; chest CT: airway dilation &amp; thickening ± cystic Δs, infiltrates, adenopathy</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre33"/>
<col class="calibre33"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Etiology</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Other Features</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Evaluation</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Chronic infxns (eg, MTb, ABPA)</p></td>
<td class="th1"><p class="tbody">Chronic cough, freq/persist infiltrate, refract asthma (ABPA)</p></td>
<td class="th1"><p class="tbody">Sputum cx (incl mycobact, fungal), ± bronch/BAL, IgE &amp; eos (ABPA)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">1° ciliary dyskin</p></td>
<td class="th1"><p class="tbody">Sinusitis, infertility, otitis</p></td>
<td class="th1"><p class="tbody">Dynein mutations</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Immunodefic</p></td>
<td class="th1"><p class="tbody">Recurrent infxns often as child</p></td>
<td class="th1"><p class="tbody">IgA, IgG, IgM, IgG subclasses</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">RA, Sjogren, ANCA</p></td>
<td class="th1"><p class="tbody">Resp sx may precede joint sx</p></td>
<td class="th1"><p class="tbody">RF, CCP, SS-A, SS-B, ANCA</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">IBD</p></td>
<td class="th1"><p class="tbody">Not relieved by bowel resection</p></td>
<td class="th1"><p class="tbody">Colonoscopy, biopsy</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">α<sub class="calibre17">1</sub>-AT deficiency</p></td>
<td class="th1"><p class="tbody">Lower lobe emphysema</p></td>
<td class="th1"><p class="tbody">α<sub class="calibre17">1</sub>-AT level and genotype</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Anatomic</p></td>
<td class="th1"><p class="tbody">R middle lobe synd. from sharp takeoff, foreign body aspiration</p></td>
<td class="th1"><p class="tbody">Bronchoscopy</p></td>
</tr>
</tbody>
</table>
<p class="h">Treatment</p>
<p class="noindent1">• Acute exacerbations: antibiotics directed against prior pathogens; if no prior Cx data → FQ</p>
<p class="noindent1">• Chronic mgmt: treat underlying condition, chest PT, inhaled hypertonic saline, bronchodil.; prophylactic azithro shown to ↓ exacerb in non-CF bronchiectasis <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2013:1251)</span></p>
<p class="noindent1">• Airway clearance: guaifenesin, instrumental devices (eg, Aerobika, Acapella), chest PT</p>
<p class="h">Non-tuberculous mycobacterium <span class="r">(NTM; eg, MAC,</span> <i class="calibre6">Mycobacterium kansaii</i><span class="r">)</span></p>
<p class="noindent1">• Chronic cough, ↓ wt; Lady Windermere syndrome: R middle lobe and lingula bronchiectasis in elderly ♀ who suppress expectoration</p>
<p class="noindent1">• Dx: CT scan (tree-in-bud, nodules, cavities, bronchiect.), sputum ×3 or BAL, AFB stain + Cx</p>
<p class="noindent1">• Treatment: susceptibility-based Rx pref over empiric Rx w/ [azithro or clarithro] + rifamycin &amp; ethambutol for ≥12 mo <span class="r1">(</span><span class="r2">CID</span> <span class="r1">2020;71:e1)</span></p>
<h2 class="ct"><a id="h29" class="calibre8"></a><a href="part0003.html#rh34" class="calibre8">CYSTIC FIBROSIS</a></h2>
<p class="h">Definition and pathophysiology <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:351)</span></p>
<p class="noindent1">• Autosomal recessive genetic disorder due to mutations in chloride channel (CFTR gene)</p>
<p class="noindent1">• ↑ mucus thickness, ↓ mucociliary clearance, ↑ infections → bronchiectasis</p>
<p class="h">Clinical features</p>
<p class="noindent1">• Recurrent PNA, sinus infections</p>
<p class="noindent1">• Distal intestinal obstruction syndrome (DIOS), pancreatic insufficiency (steatorrhea, malabsorption, failure to thrive, weight loss), CF-related diabetes, infertility</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;397:2195)</span></p>
<p class="noindent1">• Acute exacerbations: may be assoc w/ persistent drop in FEV<sub class="calibre10">1</sub> <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2010;182:627)</span>; continue aggressive airway clearance, target abx based on sputum cx (incl double coverage for PsA); common pathogens include PsA, <i class="calibre6">S. aureus</i>, non-typeable <i class="calibre6">H. flu</i>, <i class="calibre6">Stenotrophomonas</i>, <i class="calibre6">Burkholderia</i>, NTM</p>
<p class="noindent1">• Chronic mgmt: airway clearance with chest PT, inhaled hypertonic saline, inhaled DNAse (dornase alfa), SABA; oral azithromycin if chronic respiratory symptoms, inhaled tobramycin or aztreonam if persistent PsA infection</p>
<p class="noindent1">• CFTR potentiator (ivacaftor) or corrector (lumacaftor, tezacaftor) depending on mutation; combo (elexacaftor+tezacaftor+ivacaftor) if homozygous for ΔF508 <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2019;394:1940)</span></p>
<p class="noindent1">• Lung transplantation; refer to lung transplant center when FEV<sub class="calibre10">1</sub> &lt;30% predicted, rapidly declining FEV<sub class="calibre10">1</sub>, 6MWT &lt;400 m, evidence of PHT, significant clinical decline</p>
<h2 class="ct"><a id="h30" class="calibre8"></a><a id="page_2-9" class="calibre8"></a><a href="part0003.html#rh35" class="calibre8">INTERSTITIAL LUNG DISEASE</a></h2>
<p class="h1cr">W<small class="calibre31">ORKUP OF</small> ILD <span class="r3">(</span><span class="r4">Thorax</span> <span class="r3">2008;63:v1)</span></p>
<p class="noindent"><i class="calibre6">May present as incidental finding, subacute dyspnea, or rapidly progressive hypox. resp fail.</i></p>
<p class="h">Broad categories</p>
<p class="noindent1">• (1) <b class="calibre7">Sarcoid;</b> (2) <b class="calibre7">Exposures</b> (eg, drugs, XRT, organic &amp; inorganic dusts, vaping);</p>
<p class="noindent1">•  (3) <b class="calibre7">Collagen vasc dis</b> (eg, scleroderma, ANCA, myositis, RA); (4) <b class="calibre7">Idiopathic PNAs</b> (qv)</p>
<p class="h">Rule out mimickers of ILD</p>
<p class="noindent1">• <b class="calibre7">Congestive heart failure</b> (✓ BNP, trial of diuresis); <b class="calibre7">infection:</b> viral, atypical bacterial; <b class="calibre7">malignancy:</b> lymphangitic carcinomatosis, bronchoalveolar, leukemia, lymphoma</p>
<p class="h">History and physical exam</p>
<p class="noindent1">• Occupational, exposures (eg, birds), tobacco, meds, XRT, FHx, precipitating event</p>
<p class="noindent1">• Tempo (acute → infxn, CHF, hypersens pneumonitis, eos PNA, AIP, COP, drug-induced)</p>
<p class="noindent1">• Extrapulm signs/sx (skin Δs, arthralgias, arthritis, myalgias, sicca sx, alopecia, Raynaud’s)</p>
<p class="h">Diagnostic studies<span class="r"> (see Appendix &amp; Radiology inserts)</span></p>
<p class="noindent1">• CXR and <b class="calibre7">high-resolution chest CT</b></p>
<p class="noindent2">Upper lobe predom: hypersensitivty, coal, silica, smoking-related, sarcoidosis, Langerhan’s</p>
<p class="noindent2">Lower lobe predom: NSIP, UIP, asbestosis</p>
<p class="noindent2">Adenopathy: malignancy, sarcoidosis, berylliosis, silicosis</p>
<p class="noindent2">Pleural disease: collagen-vascular diseases, asbestosis, infections, XRT</p>
<p class="noindent1">• PFTs: ↓ D<sub class="calibre10">L</sub>CO (<i class="calibre6">early sign</i>), restrictive pattern (↓ volumes), ↓ P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> (esp. w/ exercise);</p>
<p class="noindent2">If restrictive + obstructive, consider sarcoid</p>
<p class="noindent2">If combined pulmonary fibrosis and emphysema (CFPE) → near-nl lung vol on PFTs</p>
<p class="noindent1">• Serologies: ✓ ACE, ANA, RF, RNP, ANCA, CCP, SSA/SSB, Scl 70, CK, aldolase, myositis panel</p>
<p class="noindent1">• Bronchoalveolar lavage: in select cases if suspect superimposed infection, hemorrhage, eosinophilic syndromes</p>
<p class="noindent1">• Bx (transbronch w/ or w/o cryo vs. VATS depending on location) if unclear etiology</p>
<p class="h1cr">S<small class="calibre31">PECIFIC</small> E<small class="calibre31">TIOLOGIES</small> <small class="calibre31">OF</small> ILD</p>
<p class="h">Sarcoidosis <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2020;201:e26;</span> <span class="r2">JAMA</span> <span class="r1">2022;327:856)</span></p>
<p class="noindent1">• Prevalence: African Americans, northern Europeans, and females; onset in 3<sup class="calibre19">rd</sup>-5<sup class="calibre19">th</sup> decade</p>
<p class="noindent1">• Pathophysiology: depression of cellular immune system peripherally, activation centrally</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre21"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Clinical Manifestations of Sarcoidosis</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Organ System</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Manifestations</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pulmonary</b></p></td>
<td class="th1"><p class="tbodyh">Hilar LAN; fibrosis; pulm hypertension. Stages: I = bilat hilar</p>
<p class="tbodyh">LAN; II = LAN + ILD; III = ILD only; IV = diffuse fibrosis.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cutaneous</b> (~15%)</p></td>
<td class="th1"><p class="tbodyh">Waxy skin plaques; lupus pernio (violaceous facial lesions)</p>
<p class="tbodyh">Erythema nodosum (red tender nodules due to panniculitis, typically on shins). Ddx: idiopathic (34%), infxn (33%, strep, TB), sarcoid (22%), drugs (OCP, PCNs), vasculitis (Behçet’s), IBD, lymphoma.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ocular</b> (10–30%)</p></td>
<td class="th1"><p class="tbodyh">Anterior &gt;posterior uveitis; ↑ lacrimal gland</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Endo &amp; renal (10%)</p></td>
<td class="th1"><p class="tbodyh">Nephrolithiasis, hypercalcemia (10%), hypercalciuria (40%) Due to vitamin D hydroxylation by macrophages</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Neuro (10% clin, 25% path)</p></td>
<td class="th1"><p class="tbodyh">CN VII palsy, periph neuropathies, CNS lesions, seizures</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Cardiac (5% clin, 25% path)</p></td>
<td class="th1"><p class="tbodyh">Conduction block, VT, CMP</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Liver, spleen, BM</p></td>
<td class="th1"><p class="tbodyh">Granulomatous hepatitis (25%), splenic &amp; BM gran. (50%)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Constitutional</p></td>
<td class="th1"><p class="tbodyh">Fever, night sweats, anorexia &amp; wt loss (a/w hepatic path)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Musculoskeletal</p></td>
<td class="th1"><p class="tbodyh">Arthralgias, periarticular swelling, bone cysts</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• <i class="calibre6">Löfgren’s syndrome:</i> erythema nodosum + hilar adenopathy + arthritis (good prognosis)</p>
<p class="noindent1">• Diagnostic studies: <b class="calibre7">LN bx</b> → <b class="calibre7">noncaseating granulomas</b> + multinucleated giant cells Endobronchial ultrasonography superior to conventional bronch <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2013;309:2457)</span> <sup class="calibre19">18</sup>FDG PET can be used to identify extent and potentially targets for dx bx ↑ <b class="calibre7">ACE</b> (Se 60%, 90% w/ active dis., Sp 80%, false ⊕ in granulomatous diseases)</p>
<p class="noindent1">• To assess extent: CXR, PFTs, full ophtho exam, ECG, CBC (lymphopenia, ↑ eos), Ca, LFTs; ± Holter, echo, cardiac MRI, brain MRI, etc., based on s/s</p>
<p class="noindent1">• Rx: <b class="calibre7">steroids</b> if sx or extrathoracic organ dysfxn (eg, prednisone 20–40 mg/d), improves sx, but doesn’t Δ long-term course; hydroxychloroquine for extensive skin disease; MTX, AZA, mycophenolate, or anti-TNF for chronic/refractory disease</p>
<p class="noindent1">• Prognosis: ~²∕³ spontaneously remit w/in 10 y (60–80% of stage I, 50–60% stage II, 30% stage III), w/ relapses uncommon; ~<sup class="calibre19">1</sup>∕³ have progressive disease</p>
<p class="h"><a id="page_2-10" class="calibre4"></a>Exposure</p>
<p class="noindent1">• <b class="calibre7">Drugs/Iatrogenic</b></p>
<p class="noindent2"><b class="calibre7">Amiodarone:</b> interstitial pneumonitis ↔ org. PNA ↔ ARDS; Rx: d/c amio; steroids</p>
<p class="noindent2">Other drugs: nitrofurantoin, sulfonamides, inh, hydralazine</p>
<p class="noindent2">Chemo: bleomycin, busulfan, cyclophosphamide, MTX, immunotherapy, XRT</p>
<p class="noindent1">• <b class="calibre7">Pneumoconioses</b> (inorganic dusts) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2000;342:406;</span> <span class="r2">Clin Chest Med</span> <span class="r1">2004;25:467)</span></p>
<p class="noindent2">Coal worker’s: upper lobe coal macules; may progress to massive fibrosis</p>
<p class="noindent2">Silicosis: upper lobe opacities ± eggshell calcification of lymph nodes; ↑ risk of TB</p>
<p class="noindent2">Asbestosis: lower lobe fibrosis, calcified pleural plaques, DOE, dry cough, rales on exam. Asbestos exposure → pleural plaques, benign pleural effusion, diffuse pleural thickening, rounded atelectasis, mesothelioma, lung Ca (esp. in smokers)</p>
<p class="noindent2">Berylliosis: multisystemic granulomatous disease that mimics sarcoidosis</p>
<p class="noindent1">• <b class="calibre7">Hypersensitivity pneumonitides</b> (organic dusts): loose, noncaseating <i class="calibre6">granulomas</i></p>
<p class="noindent2">Antigens: farmer’s lung (spores of thermophilic actinomyces); bird fancier’s lung (proteins from feathers and excreta of birds or down); humidifier lung (thermophilic bacteria)</p>
<p class="h">Collagen vascular diseases <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2013;143:814)</span></p>
<p class="noindent1">• <b class="calibre7">Rheumatologic disease</b></p>
<p class="noindent2">Scleroderma: ILD in ~50%; PHT seen in ~10% of Pts with limited disease</p>
<p class="noindent2">PM-DM: ILD &amp; skin/muscle findings; MCTD: PHT &amp; fibrosis; Sjogren’s: ILD &amp; sicca sx</p>
<p class="noindent2">SLE &amp; RA: pleuritis and pleural effusions more often than ILD; SLE can cause DAH</p>
<p class="noindent1">• <b class="calibre7">Vasculitis</b> (can p/w <i class="calibre6">DAH</i>)</p>
<p class="noindent2">Granulomatosis w/ polyangiitis (GPA): ⊕ c-ANCA w/ necrotizing granulomas</p>
<p class="noindent2">Eosinophilic GPA (EGPA): ⊕ c- or p-ANCA w/ eosinophilia &amp; necrotizing granulomas</p>
<p class="noindent2">Microscopic polyangiitis: ⊕ p-ANCA w/o granulomas</p>
<p class="noindent1">• <b class="calibre7">Goodpasture’s syndrome</b> = DAH + RPGN; typically in smokers; ⊕ anti-GBM in 90%</p>
<p class="noindent1">• <b class="calibre7">Lymphangioleiomyomatosis</b> (LAM): cystic, ↑ in ♀, Rx w/ sirolimus <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:1595)</span></p>
<p class="h">Idiopathic interstitial pneumonias (IIPs) <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2013;188:733)</span></p>
<p class="noindent1">• Definition: <b class="calibre7">ILD of unknown cause;</b> dx by radiographic, histologic, and clinical features</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre28"/>
<col class="calibre13"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">IIPs</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Type</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Imaging/Histology</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Clinical</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">IPF</p></td>
<td class="th1"><p class="tbody">UIP imaging pattern: reticular opacities, honeycombing, traction bronchiectasis; peripheral, subpleural, &amp; basal</p></td>
<td class="th1"><p class="tbody">Sx &gt;12 mo</p>
<p class="tbody">5-y mort ~80%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">NSIP</p></td>
<td class="th1"><p class="tbody">Homogenous ground-glass opacities or consolid., reticular irreg lines; subpleural sparing; symmetric, peripheral, basal. Cellular &amp; fibrotic subtypes.</p></td>
<td class="th1"><p class="tbody">Sx mos–y</p>
<p class="tbody">5-y mort 10%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">COP</p></td>
<td class="th1"><p class="tbody">Patchy, migratory consolidations; subpleural &amp; peribronchial. Excessive proliferation of granulation tissue in small airways and alveolar ducts.</p></td>
<td class="th1"><p class="tbody">Post-infxn, XRT, rxn to drug. 5-y mort &lt;5%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">AIP</p></td>
<td class="th1"><p class="tbody">Diffuse ground-glass opacities, consolidations w/ lobular sparing. Path/imaging similar to DAD (diffuse, bilateral, central&gt;periph ground glass or consolidative opacities).</p></td>
<td class="th1"><p class="tbody">Sx &lt;3 wk</p>
<p class="tbody">6-mo mort 60%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">DIP</p></td>
<td class="th1"><p class="tbody">Diffuse ground-glass opacities, reticular lines; lower zones. Peripheral macrophage in alveoli.</p></td>
<td class="th1" rowspan="2"><p class="tbody">30–50 yo <i class="calibre6">smokers</i></p>
<p class="tbody">Sx wks–mos</p>
<p class="tbody">Death rare</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">RB-ILD</p></td>
<td class="th1"><p class="tbody">Bronchial thickening, centrilobular nodules, patchy ground-glass opacities; upper lobe predom. Mφ in alveoli.</p></td>
</tr>
</tbody>
</table>
<p class="tfn">UIP, usual interstitial PNA (IP); IPF, idiopathic pulm fibrosis; NSIP, nonspecific IP; COP, cryptogenic organizing PNA; AIP, acute IP (Hamman-Rich syndrome); DIP, desquamative IP; RB-ILD, resp bronchiolitis-assoc ILD.</p>
<p class="noindent1">• Rx for IPF: suppl O<sub class="calibre10">2</sub>, pulm rehab, Rx for GERD, PHT screening, lung tx referral;</p>
<p class="noindent2"><b class="calibre7">pirfenidone</b> (antifibrotic) or <b class="calibre7">nintedanib</b> (tyrosine kinase inhib mediating fibrogenic growth factors) ↓ rate of FVC decline <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;398:1450)</span></p>
<p class="noindent2">high-dose steroids may be used for acute exacerbations, but no RCT data</p>
<p class="noindent1">• Steroids for other IIPs: NSIP (esp. cellular type) and COP <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2000;162:571)</span>; ? benefit for AIP and DIP/RB-ILD (for which Pts should stop smoking)</p>
<p class="h">Pulmonary infiltrates w/ eosinophilia (PIE) = eos on BAL é peripheral blood</p>
<p class="noindent1">• <b class="calibre7">Allergic bronchopulmonary aspergillosis (ABPA)</b></p>
<p class="noindent1">• EGPA</p>
<p class="noindent1">• Löffler’s syndrome: parasites/drugs → transient pulm infilt + cough, fever, dyspnea, eos</p>
<p class="noindent1">• Acute eosinophilic PNA (AEP): acute hypox febrile illness; Rx: steroids, tobacco cessation</p>
<p class="noindent1">• Chronic eosinophilic pneumonia (CEP): “photonegative” of CHF, typically in women</p>
<p class="h">Miscellaneous</p>
<p class="noindent1">• Pulm alveolar proteinosis (PAP): accumulation of surfactant-like phospholipids; white &amp; gummy sputum; BAL milky fluid <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:2527)</span>; Rx w/ lung lavage &amp; GMCSF</p>
<p class="noindent1">• Langerhans cell granulomatosis (LCG): young ♂ smokers; apical cysts; PTX (25%)</p>
<h2 class="ct"><a id="h31" class="calibre8"></a><a id="page_2-11" class="calibre8"></a><a href="part0003.html#rh36" class="calibre8">PLEURAL EFFUSION</a></h2>
<p class="h">Pathophysiology</p>
<p class="noindent1">• <b class="calibre7">Systemic factors</b> (eg, ↑ PCWP, ↓ oncotic pressure) → <i class="calibre6">transudative</i> effusion</p>
<p class="noindent1">• <b class="calibre7">Local factors</b> (ie, Δ pleural surface permeability) → <i class="calibre6">exudative</i> effusion</p>
<p class="h">Transudates</p>
<p class="noindent1">• <b class="calibre7">Congestive heart failure</b> (<b class="calibre7">40%</b>): 80% bilateral, ± cardiomegaly on CXR occasionally exudative (especially after aggressive diuresis or if chronic)</p>
<p class="noindent1">• <b class="calibre7">Constrictive pericarditis</b> (knock on exam, calcification or thickening on imaging)</p>
<p class="noindent1">• <b class="calibre7">Cirrhosis</b> (“hepatic hydrothorax”): diaphragmatic pores allow passage of ascitic fluid often right-sided (²∕³) &amp; massive (even w/o marked ascites)</p>
<p class="noindent1">• Nephrotic syndrome: usually small, bilateral, asymptomatic (r/o PE b/c hypercoag)</p>
<p class="noindent1">• Other: PE (usually exudate), malignancy (lymphatic obstruction), myxedema, CAPD</p>
<p class="h">Exudates</p>
<p class="noindent1">• <b class="calibre7">Lung parenchymal infection (25%)</b></p>
<p class="noindent2">Bacterial (parapneumonic): can evolve along spectrum of <i class="calibre6">exudative</i> (but sterile) → <i class="calibre6">fibropurulent</i> (infected fluid) → <i class="calibre6">organization</i> (fibrosis &amp; formation of rigid pleural peel). Common causes: <i class="calibre6">Strep pneumo, Staph aureus, Strep milleri, Klebsiella, Pseudomonas, Haemophilus, Bacteroides, Peptostreptococcus</i>, mixed flora in aspiration pneumonia.</p>
<p class="noindent2">Mycobacterial: &gt;50% lymphs 80% of the time, ADA &gt;40, pleural bx ~70% Se</p>
<p class="noindent2">Fungal, viral (usually small), parasitic (eg, amebiasis, echinococcosis, paragonimiasis)</p>
<p class="noindent1">• <b class="calibre7">Malignancy</b> (<b class="calibre7">15%</b>): primary lung cancer most common, metastases (esp. breast, lymphoma, etc.), mesothelioma (✓ serum osteopontin levels; <span class="r2">NEJM</span> <span class="r1">2005;353:15</span>)</p>
<p class="noindent1">• <b class="calibre7">Pulmonary embolism</b> (<b class="calibre7">10%</b>): effusions in ~40% of PEs; exudate (75%) &gt;transudate (25%); hemorrhagic—<i class="calibre6">must have high suspicion b/c presentation highly variable</i></p>
<p class="noindent1">• <b class="calibre7">Collagen vascular disease:</b> RA (large), SLE (small), GPA, EGPA</p>
<p class="noindent1">• <b class="calibre7">Abdominal diseases:</b> pancreatitis, cholecystitis, esophageal rupture, abdominal abscess</p>
<p class="noindent1">• Hemothorax (Hct<sub class="calibre10">eff</sub>/Hct<sub class="calibre10">blood</sub> &gt;50%): trauma, PE, malignancy, coagulopathy, leaking aortic aneurysm, aortic dissection, pulmonary vascular malformation</p>
<p class="noindent1">• Chylothorax (triglycerides &gt;110): thoracic duct damage due to trauma, malignancy, LAM</p>
<p class="noindent1">• Other:</p>
<p class="noindent2">Post-CABG: left-sided; initially bloody, clears after several wks</p>
<p class="noindent2">Dressler’s syndrome (pericarditis &amp; pleuritis post-MI), uremia, post-radiation therapy</p>
<p class="noindent2">Asbestos exposure: benign; ⊕ eosinophils</p>
<p class="noindent2">Drug-induced (eg, nitrofurantoin, methysergide, bromocriptine, amiodarone): ⊕ eos</p>
<p class="noindent2">Uremia; post-XRT; sarcoidosis</p>
<p class="noindent2">Meigs’ syndrome: benign ovarian tumor → ascites &amp; pleural effusion</p>
<p class="noindent2">Yellow-nail syndrome: yellow nails, lymphedema, pleural effusion, bronchiectasis</p>
<p class="h">Diagnostic studies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:740)</span></p>
<p class="noindent1">• <b class="calibre7">Thoracentesis</b> <span class="r">(ideally U/S guided)</span> <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2006;355:e16)</span></p>
<p class="noindent2"><i class="calibre6">Indications:</i> <b class="calibre7">all effusions</b> &gt;<b class="calibre7">1 cm in decubitus view</b></p>
<p class="noindent3">if suspect due to CHF, can diurese and see if effusions resolve (75% do so in 48 h); <i class="calibre6">asymmetry, fever</i>, <i class="calibre6">chest pain or failure to resolve</i> → thoracentesis</p>
<p class="noindent3"><b class="calibre7">parapneumonic effusions should be tapped ASAP</b> (<i class="calibre6">cannot</i> exclude infxn clinically)</p>
<p class="noindent2"><i class="calibre6">Diagnostic studies:</i> ✓ total protein, LDH, glucose, cell count w/ differential, Gram stain &amp; culture, pH; remaining fluid for additional studies as dictated by clinical scenario</p>
<p class="noindent2"><i class="calibre6">Complications:</i> PTX (5–10%), hemothorax (~1%), re-expansion pulm edema (if &gt;1.5 L removed), spleen/liver lac.; post-tap CXR not routinely needed <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">1996;124:816)</span></p>
<p class="noindent2">↓ PTX w/ U/S and experienced supervisor; even with INR ~1.9, on DOAC, or on clopi, risk of bleed low w/ U/S &amp; experienced operator <span class="r1">(</span><span class="r2">Mayo</span> <span class="r1">2019;94:1535)</span></p>
<p class="noindent1">• <b class="calibre7">Transudate vs. exudate</b> <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;311:2422)</span></p>
<p class="noindent2"><b class="calibre7">Light’s criteria:</b> exudate = TP<sub class="calibre10">eff</sub>/TP<sub class="calibre10">serum</sub> &gt;0.5 <i class="calibre6">or</i> LDH<sub class="calibre10">eff</sub>/LDH<sub class="calibre10">serum</sub> &gt;0.6 <i class="calibre6">or</i> LDH<sub class="calibre10">eff</sub> &gt;²∕³ ULN of LDH<sub class="calibre10">serum</sub>; 97% Se, 85% Sp; best Se of all methods; however, will misidentify 25% of transudates as exudates; ∴ if clinically suspect transudate but meets criterion for exudate, confirm w/ test w/ higher Sp</p>
<p class="noindent2">Exudative criteria w/ better Sp: chol<sub class="calibre10">eff</sub> &gt;55 mg/dL (95–99% Sp); chol<sub class="calibre10">eff</sub> &gt;45 mg/dL <i class="calibre6">and</i> LDH<sub class="calibre10">eff</sub> &gt;200 (98% Sp); chol<sub class="calibre10">eff</sub>/chol<sub class="calibre10">serum</sub> &gt;0.3 (94% Sp); serum-effusion alb gradient ≤1.2 (92% Sp); serum-effusion TP gradient ≤3.1 (91% Sp)</p>
<p class="noindent2">CHF effusions: <i class="calibre6">TP may</i> ↑ <i class="calibre6">with diuresis or chronicity</i> → “pseudoexudate”; alb gradient ≤1.2, chol<sub class="calibre10">eff</sub> &gt;60 mg/dL (Se 54%, Sp 92%) or clin judgment to distinguish <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2002;122:1524)</span></p>
<p class="noindent1">• <b class="calibre7">Complicated vs. uncomplicated parapneumonic</b> <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">1995;108:299)</span></p>
<p class="noindent2">complicated = ⊕ Gram stain or culture <i class="calibre6">or</i> pH &lt;7.2 <i class="calibre6">or</i> glucose &lt;60</p>
<p class="noindent2">complicated parapneumonic effusions usually require tube thoracostomy for resolution</p>
<p class="noindent2">empyema = frank pus, also needs tube thoracostomy <span class="r1">(</span><span class="r2">J Thorac CV Surg</span> <span class="r1">2017;153:e129)</span></p>
<p class="noindent1"><a id="page_2-12" class="calibre4"></a>• Additional pleural fluid studies <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;346:1971)</span></p>
<p class="noindent2">NT-proBNP ≥1500 pg/mL has 91% Se &amp; 93% Sp for CHF <span class="r1">(</span><span class="r2">Am J Med</span> <span class="r1">2004;116:417)</span></p>
<p class="noindent2">WBC &amp; diff.: exudates tend to have ↑ WBC vs. transudates but nonspecific neutrophils → parapneumonic, PE, pancreatitis lymphocytes (&gt;50%) → cancer, TB, rheumatologic eos (&gt;10%) → blood, air, drug rxn, asbestos, paragonimiasis, Churg-Strauss, PE</p>
<p class="noindent2">RBC: Hct<sub class="calibre10">eff</sub> 1–20% → cancer, PE, trauma; Hct<sub class="calibre10">eff</sub>/Hct<sub class="calibre10">blood</sub> &gt;50% → hemothorax</p>
<p class="noindent2">AFB: yield in TB 0–10% w/ stain, 11–50% w/ culture, ~70% w/ pleural bx</p>
<p class="noindent2">adenosine deaminase (ADA): seen w/ granulomas, &gt;70 suggests TB, &lt;40 excludes TB</p>
<p class="noindent2">cytology: ideally ≥150 mL and at least 60 mL should be obtained <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2010;137:68)</span></p>
<p class="noindent2">glucose: &lt;60 mg/dL → malignancy, infection, RA</p>
<p class="noindent2">amylase: seen in pancreatic disease and esophageal rupture (salivary amylase)</p>
<p class="noindent2">rheumatoid factor, C<sub class="calibre10">H</sub>50, ANA: <i class="calibre6">limited utility</i> in dx collagen vascular disease</p>
<p class="noindent2">triglycerides: &gt;110 → chylothorax, 50–110 → ✓ lipoprotein analysis for chylomicrons</p>
<p class="noindent2">cholesterol: &gt;60; seen in chronic effusions (eg, CHF, RA, old TB)</p>
<p class="noindent2">creatinine: effusion/serum ratio &gt;1 → urinothorax</p>
<p class="noindent2">fibulin-3: ↑ plasma and/or effusion levels → mesothelioma <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:1417)</span></p>
<p class="noindent1">• Chest CT; pleural biopsy; VATS</p>
<p class="noindent1">• Undiagnosed persistent pleural effusions <span class="r1">(</span><span class="r2">Clin Chest Med</span> <span class="r1">2006;27:309)</span></p>
<p class="noindent2"><i class="calibre6">Transudative:</i> most commonly CHF or hepatic hydrothorax. ✓ s/s CHF or cirrhosis, NT-proBNP<sub class="calibre10">eff</sub>; consider intraperitoneal injection of technetium-99m sulfur colloid</p>
<p class="noindent2"><i class="calibre6">Exudative</i> (ensure using Sp test listed above): most commonly malig, empyema, TB, PE. ✓ s/s malig, chest CT (I<sup class="calibre19">+</sup>), ADA or IFN-γ release assay; consider thoracoscopy.</p>
<p class="imaget"><img src="../images/00042.jpeg" alt="" class="calibre5"/></p>
<p class="h">Treatment</p>
<p class="noindent1">• Symptomatic effusion: therapeutic thoracentesis, treat underlying disease process</p>
<p class="noindent1">• Parapneumonic effusion <span class="r1">(</span><span class="r2">Chest 2000;</span><span class="r1">11</span><span class="r2">8:</span><span class="r1">11</span><span class="r2">58</span><span class="r1">)</span></p>
<p class="noindent2">uncomplicated → antibiotics for pneumonia</p>
<p class="noindent2">&gt;½ <b class="calibre7">hemithorax <i class="calibre6">or</i> complicated <i class="calibre6">or</i> empyema</b> → <b class="calibre7">tube thoracostomy</b> (otherwise risk of organization and subsequent need for surgical decortication)</p>
<p class="noindent2">loculated→ tube thoracostomy or VATS; intrapleural t-PA + DNase ↓ need for surgery</p>
<p class="noindent1">• Malignant effusion: serial thoracenteses vs. tube thoracostomy + pleurodesis (success rate ~80–90%) vs. indwelling pleural catheter, which ↓ hosp days but ↑ adverse events <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;318:1903)</span>; systemic steroids &amp; pH &lt;7.2 a/w ↑ pleurodesis failure rate</p>
<p class="noindent1">• TB effusions: effusion will often resolve spontaneously; however, treat Pt for active TB</p>
<p class="noindent1">• Hepatic hydrothorax</p>
<p class="noindent2">Rx: Δ pressure gradient (ie, ↓ ascitic fluid volume, NIPPV)</p>
<p class="noindent2">avoid chest tubes; prn thoracenteses, pleurodesis, TIPS or VATS closure of diaphragmatic defects if medical Rx fails; NIPPV for acute short-term management</p>
<p class="noindent2">spontaneous bacterial empyema (SBEM) can occur (even w/o SBP being present), ∴ thoracentesis if suspect infection</p>
<p class="noindent2">transplant is definitive treatment and workup should begin immediately</p>
<h2 class="ct"><a id="h32" class="calibre8"></a><a id="page_2-13" class="calibre8"></a><a href="part0003.html#rh37" class="calibre8">VENOUS THROMBOEMBOLISM (VTE)</a></h2>
<p class="h">Definitions</p>
<p class="noindent1">• Superficial thrombophlebitis: pain, tenderness, erythema along superficial vein</p>
<p class="noindent1">• Deep venous thrombosis (DVT): <b class="calibre7"><i class="calibre6">Proximal</i></b> = thrombosis of iliac, femoral, or popliteal veins (nb, “superficial” femoral vein part of deep venous system). <b class="calibre7"><i class="calibre6">Distal</i></b> = calf veins below knee; lower risk of PE/death than proximal <span class="r1">(</span><span class="r2">Thromb Haem</span> <span class="r1">2009;102:493)</span>.</p>
<p class="noindent1">• Pulmonary embolism (PE): thrombosis originating in venous system and embolizing to pulmonary arterial circulation; 1 case/1000 person y; 250,000/y <span class="r1">(</span><span class="r2">Archives</span> <span class="r1">2003;163:1711)</span></p>
<p class="h">Risk factors</p>
<p class="noindent1">• Virchow’s triad for thrombogenesis. <b class="calibre7">Stasis:</b> bed rest, inactivity, CHF, CVA w/in 3 mo, air travel &gt;6 h. <b class="calibre7">Injury to endothelium:</b> trauma, surgery, prior DVT, inflam, central catheter.</p>
<p class="noindent2"><b class="calibre7">Thrombophilia:</b> genetic disorders (qv), HIT, OCP, HRT, tamoxifen, raloxifene.</p>
<p class="noindent1">• Malignancy (12% of “idiopathic” DVT/PE; <span class="r2">Circ</span> <span class="r1">2013;128:2614</span>)</p>
<p class="noindent1">• History of thrombosis (greater risk of recurrent VTE than genetic thrombophilia)</p>
<p class="noindent1">• Obesity, smoking, acute infection, postpartum <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">1997;277:642;</span> <span class="r2">Circ</span> <span class="r1">2012;125:2092)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Thromboprophylaxis</b> <span class="sm">(<i class="calibre6">Blood Adv</i> 2018;2:3198)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Patient &amp; Situation</b></p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Prophylaxis</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Low-risk med; same-day surg &amp; &lt;40 y</p></td>
<td class="th1"><p class="tbody">Early, aggressive ambulation ± mechanical</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Moderate-risk (hosp., ≥1 risk factor) or high-risk medical (hosp., ICU, cancer, stroke)</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">LMWH</b> or <b class="calibre7">UFH</b> (if renal failure) or fonda (if HIT ⊕). Pharmacologic favored vs. mechanical, but may personalize based on bleeding &amp; thrombotic risk.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Low-risk surgery (minor surgery)</p></td>
<td class="th1"><p class="tbody">Mechanical Ppx</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Moderate-risk surgery (eg, major surgery, trauma, immobilization)</p></td>
<td class="th1"><p class="tbody">If low bleeding risk: <b class="calibre7">LMWH</b> or <b class="calibre7">UFH</b> SC</p>
<p class="tbody">If high bleeding risk: <b class="calibre7">mech Ppx</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">High-risk nonorthopedic surgery (multiple risk factors), stroke or ICH</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">[LMWH</b> or <b class="calibre7">UFH</b> SC<b class="calibre7">] + mech</b>. Stroke s/p lytic or ICH: mech 24 h or until bleed stable, then + pharm.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Ortho surgery (cont pharmacoRx up to 35 d [hip] or 10–14 d [knee])</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">LMWH</b> or <b class="calibre7">DOAC</b> (or fonda, UFH, or warfarin [INR 2–3]) <b class="calibre7">+ mech Ppx.</b></p></td>
</tr>
</tbody>
</table>
<p class="tfn">UFH: 5000 U SC bid or tid. Enox: 30 mg bid for highest risk or 40 mg qd for moderate risk or spinal/epidural anesthesia. For riva 10 mg/d, apixa 2.5 mg/d, edox 30 mg/d, dabi 110 mg post-op and then 220 mg/d.</p>
<p class="h"><a id="page_2-14" class="calibre4"></a>Clinical manifestations—DVT</p>
<p class="noindent1">• Calf pain, swelling (&gt;3 cm c/w unaffected side), venous distention, erythema, warmth, tenderness, palpable cord, ⊕ Homan’s sign (calf pain on dorsiflexion, seen in &lt;5%)</p>
<p class="noindent1">• 50% of Pts with sx DVT have asx PE</p>
<p class="noindent1">• Popliteal (Baker’s) cyst: may lead to DVT due to compression of popliteal vein</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre12"/>
<col class="calibre33"/>
<col class="calibre34"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">“Simplified Wells” Pretest Probability Scoring of DVT</b> <span class="sm">(<i class="calibre6">JAMA</i> 2006;295:199)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1" colspan="3"><p class="tbodyh">+1 point each for: active cancer (Rx ongoing or w/in 6 mo or palliative); paralysis, paresis, or recent immobilization of lower extremities; recently bedridden for ≥3 d or major surgery w/in 12 wk; localized tenderness along distribution of deep venous system; entire leg swelling; calf ≥3 cm larger than asx calf (at 10 cm below tibial tuberosity); pitting edema confined to sx leg; collateral superficial veins (nonvaricose); previous DVT</p>
<p class="tbodyh">–2 points if alternative dx at least as likely as DVT</p></td>
</tr>
<tr class="calibre15">
<td colspan="3" class="th"><p class="tbodyc"><b class="calibre7">Pretest Probability Assessment</b> (useful if outPt, less so if inPt; <span class="sm"><i class="calibre6">JAMA IM</i> 2015;175:1112</span>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Score ≤0</p></td>
<td class="th1"><p class="tbodyc">Score 1 or 2</p></td>
<td class="th1"><p class="tbodyc">Score ≥3</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Low probability (5%)</p></td>
<td class="th1"><p class="tbodyc">Moderate probability (17%)</p></td>
<td class="th1"><p class="tbodyc">High probability (53%)</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• For UE DVT, +1 point each for venous cath, local pain, &amp; unilateral edema, –1 if alternative dx. ≤1 = unlikely; ≥2 = likely. U/S if likely or if unlikely but abnl D-dimer <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2014;160:451)</span></p>
<p class="h">Diagnostic studies—DVT</p>
<p class="noindent1">• D-dimer: &lt;500 helps r/o; ? use 1000 as threshold if low risk <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2013;158:93)</span></p>
<p class="noindent1">• Compression U/S &gt;95% Se &amp; Sp for sx DVT (lower if asx); survey whole leg if ≥ mod prob</p>
<div class="cap">
<p class="caption"><a id="fig2-3" class="calibre4"></a><b class="calibre7">Figure 2-3</b> Approach to suspected DVT</p>
<p class="imagef1"><img src="../images/00043.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Clinical manifestations—PE</p>
<p class="noindent1">• Dyspnea (~50%), pleuritic chest pain (~40%), cough (~23%), hemoptysis (~8%)</p>
<p class="noindent1">• ↑ RR (&gt;70%), crackles (51%), ↑ HR (30%), fever, cyanosis, pleural friction rub, loud P<sub class="calibre10">2</sub></p>
<p class="noindent1">• <i class="calibre6">Massive:</i> syncope, HoTN, PEA; ↑ JVP, R-sided S<sub class="calibre10">3</sub>, Graham Steell (PR) murmur</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre21"/>
<col class="calibre20"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Modified Wells Pretest Probability Scoring for PE</b> <span class="sm">(<i class="calibre6">Annals</i> 2011;154:709)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="tbn"><p class="tnl"><span class="tft">•</span> Prior PE or DVT=1.5 points</p>
<p class="tnl"><span class="tft">•</span> Active cancer =1.0</p>
<p class="tnl"><span class="tft">•</span> Immobilization (bed rest ≥3 d) or surgery w/in 4 wk=1.5</p>
<p class="tnl"><span class="tft">•</span> Alternative dx less likely than PE=3</p></td>
<td class="tbn">
<p class="tnl"><span class="tft">•</span> Clinical signs of DVT=3</p>
<p class="tnl"><span class="tft">•</span> HR &gt;100 bpm=1.5</p>
<p class="tnl"><span class="tft">•</span> Hemoptysis=1.0</p>
</td>
</tr>
<tr class="calibre15">
<td colspan="2" class="th"><p class="tbodyc"><b class="calibre7">Simplified Wells Probability Assessment</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">≤4 = ”Unlikely” (13% probability)</p></td>
<td class="th1"><p class="tbodyh">&gt;4 “Likely” (39% probability)</p></td>
</tr>
</tbody>
</table>
<p class="h">Diagnostic studies—PE <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2014;35:3033)</span></p>
<p class="noindent1">• CXR (limited Se &amp; Sp): 12% nl, atelectasis, effusion, ↑ hemidiaphragm, Hampton hump (wedge-shaped density abutting pleura); Westermark sign (avascularity distal to PE)</p>
<p class="noindent1">• ECG (limited Se &amp; Sp): sinus tachycardia, AF; signs of RV strain → RAD, P pulmonale, RBBB, S<sub class="calibre10">I</sub>Q<sub class="calibre10">III</sub>T<sub class="calibre10">III</sub> &amp; TWI V<sub class="calibre10">1</sub>–V<sub class="calibre10">4</sub> (McGinn-White pattern; <span class="r2">Chest</span> <span class="r1">1997;111:537</span>)</p>
<p class="noindent1">• ABG: hypoxemia, hypocapnia, respiratory alkalosis, ↑ A-a gradient <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">1996;109:78)</span> 18% w/ room air P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> 85–105 mmHg, 6% w/ nl A-a gradient <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">1991;100:598)</span></p>
<p class="noindent1">• D-dimer: high Se, poor Sp (~25%); ELISA has &gt;99% NPV ∴ use to r/o PE if “unlikely” pretest prob <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2006;295:172)</span>; cut-off 500 if &lt;50 y, 10× age if ≥ 50 y <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;311:1117)</span></p>
<p class="noindent1">• Echocardiography: useful for risk stratification (RV dysfxn), but not dx (Se &lt;50%)</p>
<p class="noindent1">• V/Q scan: high Se (~98%), low Sp (~10%). Sp improves to 97% for high-prob VQ. Use if pretest prob of PE high and CT not available or contraindicated. Can also exclude PE if low pretest prob, low-prob VQ, but 4% false <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">1990;263:2753)</span>.</p>
<p class="noindent1">• <b class="calibre7">CT angiography</b> (CTA; see Radiology inserts; <span class="r2">JAMA</span> <span class="r1">2015;314:74)</span>: Se ~90% &amp; Sp ~95%; PPV &amp; NPV &gt;95% if imaging concordant w/ clinical suspicion, ≤80% if discordant (∴ need to consider both); ~1/4 of single &amp; subseg may be false ⊕; CT may also provide other dx</p>
<p class="noindent1">• Lower extremity compression U/S shows DVT in ~9%, sparing CTA</p>
<div class="cap">
<p class="caption"><a id="fig2-4" class="calibre4"></a><b class="calibre7">Figure 2-4</b> Approach to suspected PE</p>
<p class="imagef1"><img src="../images/00044.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Workup for idiopathic VTE <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:697)</span></p>
<p class="noindent1">• <b class="calibre7">Thrombophilia workup:</b> ✓ if ⊕ FH; may be helpful but consider timing as thrombus, heparin and warfarin Δ results. Useful for relatives, if dx APLAS (given requires warfarin), or if not planning lifelong anticoagulation for Pt.</p>
<p class="noindent1">• <b class="calibre7">Malignancy workup:</b> 12% Pts w/ “idiopathic” DVT/PE will have malignancy; age-appropriate screening adequate; avoid extensive w/u</p>
<p class="h">Risk stratification for Pts with PE</p>
<p class="noindent1">• <b class="calibre7">Clinical</b>: Simplified PE Severity Index (sPESI) risk factors include age &gt;80 y; h/o cancer; h/o cardiopulm. disease; HR ≥110; SBP &lt;100; S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> &lt;90%</p>
<p class="noindent1">• <b class="calibre7">Imaging</b>: TTE for RV dysfxn; CTA for RV/LV dimension ratio &gt;0.9. <b class="calibre7">Biomarker</b>: Tn &amp; BNP.</p>
<p class="noindent1">• <b class="calibre7">Classification</b> <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2020;41:543)</span></p>
<p class="noindent2"><b class="calibre7">High risk (“massive”)</b>: hemodyn unstable w/ arrest, obstructive shock, or persistent HoTN</p>
<p class="noindent2"><b class="calibre7">Intermediate risk (“submassive”)</b>: sPESI ≥1</p>
<p class="noindent2">“Intermediate-high” if <i class="calibre6">both</i> RV dysfunction &amp; elevated Tn</p>
<p class="noindent2">“Intermediate-low” if <i class="calibre6">either</i> or <i class="calibre6">neither</i> RV dysfunction or elevated Tn</p>
<p class="noindent2"><b class="calibre7">Low risk</b>: clinically stable, sPESI = 0, normal RV function, normal Tn</p>
<p class="h">Whom to treat <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020;324:1765;</span> <span class="r2">Chest</span> <span class="r1">2021;160:e545)</span></p>
<p class="noindent1">• <b class="calibre7">Superficial venous thrombosis:</b> elevate extremity, warm compresses, compression stockings, NSAIDs for sx. <i class="calibre6">Anticoag</i> if high risk for DVT (eg, ≥5 cm, proximity to deep vein ≤5 cm, other risk factors) for 4 wk as ~10% have VTE w/in 3 mo <span class="r1">(</span><span class="r2">Annals</span> <span class="r1">2010;152:218)</span>.</p>
<p class="noindent1">• <b class="calibre7">LE DVT:</b> proximal → anticoag; distal → anticoag if severe sx, o/w consider serial imaging over 2 wk and anticoag if extends (although if bleeding risk low, many would anticoag).</p>
<p class="noindent1"><a id="page_2-15" class="calibre4"></a>• <b class="calibre7">UE DVT:</b> anticoagulate (same guidelines as LE; <span class="r2">NEJM</span> <span class="r1">2011;364:861)</span>. If catheter-associated, need not remove if catheter functional and ongoing need for catheter.</p>
<p class="noindent1">• <b class="calibre7">PE:</b> anticoagulate (unless isolated subsegmental and risk for recurrent VTE low)</p>
<p class="h">Initial anticoagulation options <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2020;41:543;</span> <span class="r2">Chest</span> <span class="r1">2021;160:e545)</span></p>
<p class="noindent1">• <i class="calibre6">Initiate immediately if high or intermed suspicion but dx test results will take ≥4 h</i></p>
<p class="noindent1">• Either (a) initial parenteral → long-term oral or (b) solely DOAC if no interven. planned</p>
<p class="noindent1">• <b class="calibre7">LMWH</b> (eg, enoxaparin 1 mg/kg SC bid <i class="calibre6">or</i> dalteparin 200 IU/kg SC qd)</p>
<p class="noindent2">Preferred over UFH (especially in <i class="calibre6">cancer</i>) except: renal failure (CrCl &lt;25), ? extreme obesity, hemodynamic instability or bleed risk <span class="r1">(</span><span class="r2">Cochrane</span> <span class="r1">2004;CD001100)</span></p>
<p class="noindent1">• <b class="calibre7">IV UFH:</b> 80 U/kg bolus → 18 U/kg/h → titrate to PTT 1.5–2.3 × cntl (eg, 60–85 sec); preferred option when contemplating thrombolysis or catheter-based Rx (qv)</p>
<p class="noindent1">• IV direct thrombin inhibitors (eg, argatroban, bivalirudin) used in HIT ⊕ Pts</p>
<p class="noindent1">• <b class="calibre7">Fondaparinux:</b> 5–10 mg SC qd <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;349:1695)</span>; use if HIT ⊕; avoid if renal failure</p>
<p class="noindent1">• <b class="calibre7">Direct oral anticoag</b> (DOAC; <span class="r2">NEJM</span> <span class="r1">2010;363:2499; 2012;366:1287; 2013;369:799 &amp; 1406</span>)</p>
<p class="noindent2"><i class="calibre6">Preferred</i> b/c as good/better than warfarin in preventing recurrent VTE w/ less bleeding</p>
<p class="noindent2">Apixaban (10 mg bid × 7 d → 5 bid) or rivaroxaban (15 mg bid for 1st 3 wk → 20 mg/d) can be given as sole anticoagulant w/ initial loading dose</p>
<p class="noindent2">Edoxaban or dabigatran can be initiated after ≥<i class="calibre6">5 d of parenteral anticoag</i></p>
<p class="noindent1">• DVT &amp; low-risk PE w/o comorbidities and able to comply with Rx can be treated as outPt</p>
<p class="noindent1">• Generally safe to anticoagulate if platelets &gt;50,000 but contraindicated if &lt;20,000</p>
<p class="h">Systemic thrombolysis <span class="r1">(</span><span class="r2">EHJ</span> <span class="r1">2020;41:543;</span> <span class="r2">Chest</span> <span class="r1">2021;160:e545)</span></p>
<p class="noindent1">• Typically TPA 100 mg over 2 h or wt-adjusted TNK bolus; risk of ICH ~2-5%, ↑ w/ age</p>
<p class="noindent1">• Consider if low bleed risk w/ acute PE + HoTN or cardiopulm deterioration after anticoag</p>
<p class="noindent1">• <b class="calibre7">High-risk PE:</b> ↓ death &amp; recurrent PE each by ~50% <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;311:2414;</span> <span class="r2">EHJ</span> <span class="r1">2015;36:605)</span></p>
<p class="noindent1">• <b class="calibre7">Intermediate-risk PE:</b> ↓ hemodyn decompensation, ↑ ICH &amp; major bleeding, ↓ mortality in short- but not long-term; ? consider if &lt;75 y and/or low bleed risk <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2014;311:2414)</span></p>
<p class="noindent1">• <i class="calibre6">Half-dose lytic</i> (50 mg or 0.5 mg/kg if &lt;50 kg; 10-mg bolus → remainder over 2 h) in ~intermed. PE: ↓ pulm HTN &amp; ? PE or death w/ ≈ bleeding vs. heparin alone <span class="r1">(</span><span class="r2">AJC</span> <span class="r1">2013;111:273)</span></p>
<p class="noindent1">• <b class="calibre7">DVT:</b> consider if (a) acute (&lt;14 d) &amp; extensive (eg, iliofemoral), (b) severe sx swelling or ischemia, and (c) low bleed risk</p>
<p class="h">Mechanical intervention <span class="r1">(</span><span class="r2">JACC</span> <span class="r1">2020;76:2117)</span></p>
<p class="noindent1">• <b class="calibre7">Catheter-directed</b> pharmacomech: low-dose lytic infused (eg, tPA 1 mg/h for 12–24 hr per catheter) + U/S or mech fragmentation of clot. Consider if hemodyn. compromise or high risk &amp; not candidate for systemic lysis or surgical thrombectomy. Preferred to systemic lytic by some centers. Also consider if intermediate-high risk and evidence of early hemodynamic deterioration <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2014;129:479)</span>. Lack of data on hard outcomes.</p>
<p class="noindent1">• <b class="calibre7">Catheter-based clot extraction</b> (eg, AngioVac or FlowTriever): ↓ PA pressure</p>
<p class="noindent1">• <b class="calibre7">Surgical embolectomy:</b> if large, proximal PE + hemodynamic compromise + contraindic. to lysis; consider in experienced ctr if large prox. PE + RV dysfxn</p>
<p class="noindent1">• <b class="calibre7">IVC filter:</b> use if anticoag contraindic.; no benefit to adding to anticoag <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2015;313:1627)</span></p>
<p class="noindent2">Complications: migration, acute DVT, ↑ risk of recurrent DVT &amp; IVC obstruction (5–18%)</p>
<p class="h">Duration of full-intensity anticoagulation</p>
<p class="noindent1">• Superficial venous thrombosis: 4 wk</p>
<p class="noindent1">• 1<sup class="calibre19">st</sup> prox DVT <i class="calibre6">or</i> PE 2° reversible/time-limited risk factor <i class="calibre6">or</i> distal DVT: 3–6 mo</p>
<p class="noindent1">• 1<sup class="calibre19">st</sup> <i class="calibre6">unprovoked</i> prox DVT/PE: ≥3 mo, then reassess; benefit to prolonged Rx. Consider clot, bleed risk, Pt preference, and intensity of Rx when crafting strategy.</p>
<p class="noindent1">• 2<sup class="calibre19">nd</sup> VTE event or cancer: indefinite (or until cancer cured) <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;348:1425)</span></p>
<p class="h">Long-term anticoagulation options</p>
<p class="noindent1">• For nonpregnant Pt without severe renal dysfunction or active cancer → DOAC</p>
<p class="noindent1">• For severe renal insufficiency or APLAS → warfarin. Start w/ parenteral anticoag unless ? need for lytic, catheter-based Rx or surg; bridge to INR ≥2 × ≥24 h.</p>
<p class="noindent1">• Pregnancy or unable to take oral therapy → LMWH or fondaparinux</p>
<p class="noindent1">• Cancer → DOAC (but in Pts w/ UGI cancers, more GI bleeding w/ riva) or LMWH</p>
<p class="h">Extended DOAC strategies</p>
<p class="noindent1">• After ≥6 mo of anticoag, following regimens compared w/ no extended Rx (or ASA):</p>
<p class="noindent1">• Full-dose DOAC: 80–90% ↓ recurrent VTE, 2–5× bleeding, but no signif excess in major bleeding <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;363:2499; 2013;368:699 &amp; 709)</span></p>
<p class="noindent1">• ½ dose apixa or riva: ≥75% ↓ recur. VTE, w/o ↑ bleeding <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:699 &amp; 2017;376:1211)</span></p>
<p class="h">Complications &amp; prognosis</p>
<p class="noindent1">• Postthrombotic syndrome (23–60%): pain, edema, venous ulcers</p>
<p class="noindent1">• Recurrent VTE: 1%/y (after 1<sup class="calibre19">st</sup> VTE) to 5%/y (after recurrent VTE)</p>
<p class="noindent1">• Chronic thromboembolic PHT after acute PE ~2–3%, consider thromboendarterectomy</p>
<p class="noindent1">• Mortality: ~10% for DVT and ~10–15% for PE at 3–6 mo <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2008;117:1711)</span></p>
<h2 class="ct"><a id="h33" class="calibre8"></a><a id="page_2-16" class="calibre8"></a><a href="part0003.html#rh38" class="calibre8">PULMONARY HYPERTENSION (PHT)</a></h2>
<p class="center">PHT defined as PA mean pressure ≥20 mmHg at rest <span class="r1">(</span><span class="r2">ERJ</span> <span class="r1">2019;53:1801913)</span><br class="calibre1"/><i class="calibre6">PA mean</i> = <i class="calibre6">CO</i> × <i class="calibre6">PVR</i> + <i class="calibre6">PA wedge pressure. Trans pulm gradient</i> = <i class="calibre6">PA mean – PA wedge.</i></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies (Revised WHO Classification)</b> <span class="sm">(<i class="calibre6">JACC</i> 2013;62:D34)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyh"><b class="calibre7">Primary pulmonary arterial HTN (PAH)</b> (group 1)</p>
<p class="tbodyh">Precapillary PHT</p>
<p class="tbodyh">PCWP ≤15 mmHg</p>
<p class="tbodyh">↑ transpulm grad</p>
<p class="tbodyh">↑ PVR</p></td>
<td class="th1"><p class="tnl"><span class="tft">•</span> Idiopathic (IPAH): yearly incidence 1–2 per million; mean age of onset 36 y (♂ older than ♀); ♂: ♀ = ~2:1, usually mild ↑ in PAP</p>
<p class="tnl"><span class="tft">•</span> Familial (FPAH)</p>
<p class="tnl"><span class="tft">•</span> Associated conditions (APAH)</p>
<p class="tnl"><span class="tft">•</span> Connective tissue dis.: CREST, SLE, MCTD, RA, PM, Sjögren</p>
<p class="tnl"><span class="tft">•</span> Congenital L→R shunts: ASD, VSD, PDA</p>
<p class="tnl"><span class="tft">•</span> Portopulmonary HTN (? 2° vasoactive substances not filtered in ESLD; ≠ hepatopulmonary syndrome)</p>
<p class="tnl"><span class="tft">•</span> HIV; drugs &amp; toxins: anorexic agents, SSRIs, <small class="sm">l</small>-tryptophan</p>
<p class="tnl"><span class="tft">•</span> Pulmonary veno-occlusive disease: ? 2° chemo, BMT; orthopnea, pl eff, CHF, nl PCWP; art vasodil. <i class="calibre6">worsen</i> CHF <span class="sm">(<i class="calibre6">AJRCCM</i> 2000;162:1964)</span></p>
<p class="tnl"><span class="tft">•</span> Pulmonary capillary hemangiomatosis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Left heart disease</b> (group 2). ↑ PCWP</p></td>
<td class="th1"><p class="tnl"><span class="tft">•</span> Left atrial or ventricular (diastolic or systolic) dysfunction</p>
<p class="tnl"><span class="tft">•</span> Left-sided valvular heart disease (eg, MS/MR)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Lung diseases and/ or chronic hypoxemia</b> (group 3)</p></td>
<td class="th1"><p class="tnl"><span class="tft">•</span> COPD</p>
<p class="tnl"><span class="tft">•</span> Alveolar hypoventilation (eg, NM disease)</p>
<p class="tnl"><span class="tft">•</span> ILD</p>
<p class="tnl"><span class="tft">•</span> Chronic hypoxemia (eg, high altitude)</p>
<p class="tnl"><span class="tft">•</span> Sleep apnea</p>
<p class="tnl"><span class="tft">•</span> Developmental abnormalities</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Chronic thrombo- embolic dis</b> (group 4)</p></td>
<td class="th1"><p class="tnl"><span class="tft">•</span> Prox or distal PEs; ~½ w/o clinical h/o PE <span class="sm">(<i class="calibre6">NEJM</i> 2011;364:351)</span></p>
<p class="tnl"><span class="tft">•</span> Nonthrombotic emboli (tumor, foreign body, parasites)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Miscellaneous/ Multifactorial</b> (group 5)</p></td>
<td class="th1"><p class="tnl"><span class="tft">•</span> Sarcoidosis, histiocytosis X, LAM, schistosomiasis, ESRD</p>
<p class="tnl"><span class="tft">•</span> Compression of pulm vessels (adenopathy, tumor, fibrosing mediastinitis, histoplasmosis, XRT)</p>
<p class="tnl"><span class="tft">•</span> Other: thyroid dis., glycogen storage dis., Gaucher dis, HHT, sickle cell, etc., chronic myeloprolif d/o, splenectomy</p></td>
</tr>
</tbody>
</table>
<p class="h">Clinical manifestations</p>
<p class="noindent1">• Dyspnea, exertional syncope (hypoxia, ↓ CO), exertional chest pain (RV ischemia)</p>
<p class="noindent1">• Symptoms of R-sided CHF (eg, peripheral edema, RUQ fullness, abdominal distention)</p>
<p class="noindent1">• WHO class: I = asx w/ ordinary activity; II= sx w/ ord. activ; III = sx w/ min activ.; IV = sx at rest</p>
<p class="h">Physical exam</p>
<p class="noindent1">• PHT: prominent P<sub class="calibre10">2</sub>, R-sided S<sub class="calibre10">4</sub>, RV heave, PA tap &amp; flow murmur, PR (Graham Steell), TR</p>
<p class="noindent1">• ± RV failure: ↑ JVP, hepatomegaly, peripheral edema</p>
<p class="h">Diagnostic studies &amp; workup <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2022;327:1379)</span></p>
<p class="noindent1">• High-res chest CT: dilat. &amp; pruning of pulm arteries, ↑ RA &amp; RV; r/o parenchymal lung dis.</p>
<p class="noindent1">• ECG: RAD, RBBB, RAE (“P pulmonale”), RVH (Se 55%, Sp 70%)</p>
<p class="noindent1">• PFTs: disproportionate ↓ D<sub class="calibre10">L</sub>CO, mild restrictive pattern; r/o obstructive &amp; restrictive lung dis.</p>
<p class="noindent1">• ABG &amp; polysomnography: ↓ P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> and S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> (espec w/ exertion), ↓ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub>, ↑ A-a gradient; r/o hypoventilation and OSA</p>
<p class="noindent1">• TTE: ↑ RVSP (but estimate over/under by ≥10 mmHg in ½ of PHT Pts; <span class="r2">Chest 20</span><span class="r1">11</span><span class="r2">;</span><span class="r1">1</span><span class="r2">39:988</span>) ↑ RA, RV, &amp; PA; ↑ pressure → interventricular septum systolic flattening (“D” shape) ↓ RV systolic fxn (TAPSE &lt;1.6 cm); TR, PR; r/o LV dysfxn, MV, AoV, congenital disease</p>
<p class="noindent1">• RHC: ↑ RA, RV, &amp; PA pressures; ✓ L-sided pressures and for shunt</p>
<p class="noindent2">if PAH: nl PCWP, ↑ transpulmonary gradient (mean PAP-PCWP &gt;12–15), ↑ diastolic pulmonary gradient (PA diastolic – PCWP &gt;7), ↑ PVR, ± ↓ CO</p>
<p class="noindent2">if 2° to L-heart disease: PCWP (or LVEDP) &gt;15; if PVR nl → “passive PHT”; PVR &gt;240 suggests mixed picture: if ↓ PCWP → ↓ PVR, then “reactive” PHT; if no Δ, then “fixed”</p>
<p class="noindent1">• CTA (large/med vessel), V/Q scan (small vessel to r/o CTEPH), ± pulm angio if ↑ concern</p>
<p class="noindent1">• Labs: ANA (~40% ⊕ in PAH), anti-Scl-70, anti-RNP; LFTs; HIV</p>
<p class="noindent1">• 6-min walk test (6MWT) or cardiopulmonary exercise testing to establish fxnl capacity</p>
<p class="h">Treatment <span class="r1">(</span><span class="r2">JAMA</span><span class="r1"> 2022;327:1379)</span></p>
<p class="noindent1">• Principles: 1) prevent &amp; reverse vasoactive substance imbalance and vascular remodeling 2) prevent RV failure: ↓ wall stress (↓ PVR, PAP, RV diam); ensure adeq systemic DBP</p>
<p class="noindent1">• <b class="calibre7">Supportive</b></p>
<p class="noindent2">Oxygen: maintain S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> &gt;90–92% (reduces vasoconstriction)</p>
<p class="noindent2">Diuretics: ↓ RV wall stress and relieve RHF sx; <i class="calibre6">gentle</i> b/c RV is preload dependent</p>
<p class="noindent2">Anticoag: not routinely used; ↓ VTE risk of RHF; ? prevention of <i class="calibre6">in situ</i> microthrombi; ? mortality benefit even if in NSR, no RCTs <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2006;130:545)</span></p>
<p class="noindent2">Supervised exercise training; aggressive apnea/hypoventilatory Rx w/ CPAP/BiPAP</p>
<p class="noindent1"><a id="page_2-17" class="calibre4"></a>• <b class="calibre7">Vasodilators</b> (ideally right heart catheterization prior to initiation; <span class="r2">NEJM</span> <span class="r1">2004;351:1425</span>) <i class="calibre6">acute vasoreactivity test:</i> use inh NO, adenosine or prostacyclin to identify Pts likely to have long-term response to CCB (⊕ response = ↓ PAP ≥10 mmHg to &lt;40 mmHg w/ ↑ or stable CO); ~10% Pts acute responders; no response → still candidate for other vasodilators</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbody"><b class="calibre7">Vasoactive Agents</b></p></td>
<td class="th"><p class="tbody"><b class="calibre7">Comments</b> (data primarily in Group 1)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">PDE-5 inhibitor</b> sildenafil, tadalafil, vardenafil</p></td>
<td class="th1"><p class="tbody">↑ cGMP → vasodilatation, ↓ smooth muscle proliferation, ↓ sx, ↑ 6MWT, no data on clinical outcomes. Often 1<sup class="calibre27">st</sup> line b/c minimal side-effect profile: HA, vision Δ’s, sinus congestion.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Endothelin receptor antagonists (ERAs)</b> bosentan, ambrisentan, macitentan</p></td>
<td class="th1"><p class="tbody">↓ Smooth muscle remodeling, vasodilatation, ↓ fibrosis, ↓ sx, ↑ 6MWT, ↓ worsening PAH or need for prostanoids w/ trend for ↓ PAH mortality (w/ macitentan). Side effects: ↑ LFTs, HA, anemia, edema, teratogen <span class="sm">(<i class="calibre6">NEJM</i> 2013;369:809)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">IV prostacyclin</b> epoprostenol (Flolan)</p></td>
<td class="th1"><p class="tbody">Vasodilatation, ↓ plt agg, ↓ smooth muscle prolif; benefits ↑ w/ time (? vasc remodeling). ↑ 6MWT, ↑ QoL, <b class="calibre7">↓ mortality</b>. Side effects: HA, flushing, jaw pain, abd cramps, N/V, diarrhea, catheter infxn.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Prostacyclin analogs</b> [iloprost (inh), treprostinil (IV, inh, SC)]</p></td>
<td class="th1"><p class="tbody">Same mech as prostacyclin IV, but easier admin, ↓ side effects, w/o risk of catheter infxn. ↓ sx, ↑ 6MWT. Inh Rx w/ improved V/Q matching. Inh trepostinil ↑ 6MWT in ILD-PH <span class="sm">(<i class="calibre6">NEJM</i> 2021;384:325)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Prostacyclin receptor agonist</b> (selexipag, PO)</p></td>
<td class="th1"><p class="tbody">Indicated for WHO Group I to delay disease progression and risk of hospitalization. Add in WHO FC II &amp; III <span class="sm">(<i class="calibre6">NEJM</i> 2015;373:2522)</span>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Soluble guanylate cyclase stimulator</b> riociguat</p></td>
<td class="th1"><p class="tbody">NO-independent ↑ cGMP → vasodilatation, ↓ smooth muscle -proliferation, ↓ sx, ↑ 6MWT in PAH; ↓ sx, ↓ PVR, ↑ 6MWT in CTEPH <span class="sm">(<i class="calibre6">NEJM</i> 2013;369:319 &amp; 330)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Oral CCB</b> nifedipine, diltiazem</p></td>
<td class="th1"><p class="tbody">Consider if ⊕ acute vasoreactive response. Not 1st line b/c side effects: HoTN, lower limb edema.</p></td>
</tr>
</tbody>
</table>
<p class="noindent1">• Upfront combination Rx (PDE-5 inhibitor + ERA vs. monotherapy): ↓ sx, ↓ NT-proBNP, ↑ 6MWT, ↓ hospitalizations <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;373:834)</span></p>
<p class="noindent1">• Treat underlying causes of 2° PHT; can use vasodilators, although little evidence</p>
<p class="noindent1">• CTEPH: riociguat. Pulm endarterectomy potentially curative <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2011;183:1605)</span> vs. balloon pulmonary angioplasty in non-operative Pts <span class="r1">(</span><span class="r2">Circ Outcomes</span> <span class="r1">2017;10:e004029)</span>.</p>
<p class="noindent1">• Refractory PHT: balloon atrial septostomy: R→L shunt causes ↑ CO, ↓ S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>, net ↑ tissue O<sub class="calibre10">2</sub> delivery; lung txp (single or bilateral; heart-lung needed if Eisenmenger physiology)</p>
<p class="noindent1">• PHT risk stratification based on CHF symptoms, syncope, WHO functional class, 6MWT, CPET, NTproBNP, imaging, hemodynamics <span class="r1">(</span><span class="r2">Eur Heart J</span> <span class="r1">2016;37:67)</span></p>
<div class="cap">
<p class="caption"><a id="fig2-5" class="calibre4"></a><b class="calibre7">Figure 2-5</b> Treatment of PAH <span class="sm">(modified from <i class="calibre6">ERJ</i> 2019;53:1801889)</span></p>
<p class="imagef1"><img src="../images/00045.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="h">Management of ICU patient</p>
<p class="noindent1">• Avoid tachyarrhythmias &amp; overly aggressive volume resuscitation</p>
<p class="noindent1">• Caution w/ vasodilators if any L-sided dysfunction</p>
<p class="noindent1">• <i class="calibre6">Intubation can cause hemodynamic collapse</i></p>
<p class="noindent1">• Dobutamine and inhaled NO or prostacyclin</p>
<p class="noindent1">• Consider R-sided mechanical support <span class="r1">(</span><span class="r2">Circ</span> <span class="r1">2015;132:536)</span></p>
<p class="noindent1">• Consider fibrinolysis if acute, refractory decompensation (eg, TPA 100 mg over 2 h)</p>
<p class="h">Prognosis</p>
<p class="noindent1">• Median survival after dx ~2.8 y; PAH (all etiologies): 2-y 66%, 5-y 48% <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2004;126:78–S)</span></p>
<p class="noindent1">• Poor prognostic factors: clinical evidence of RV failure, rapidly progressive sx, WHO (modified NYHA) class IV, 6MWT &lt;300 m, peak VO<sub class="calibre10">2</sub> &lt;10.4 mL/kg/min, ↑ RA or RV or RV dysfxn, RA &gt;20 or CI &lt;2.0, ↑ BNP <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2006;129:1313)</span></p>
<h2 class="ct"><a id="h34" class="calibre8"></a><a id="page_2-18" class="calibre8"></a><a href="part0003.html#rh39" class="calibre8">RESPIRATORY FAILURE</a></h2>
<p class="image1"><img src="../images/00046.jpeg" alt="" class="calibre5"/></p>
<p class="noindent1">• <b class="calibre7">A-a gradient</b> =<b class="calibre7"> P<sub class="calibre10">A</sub>O<sub class="calibre10">2</sub> – P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>:</b> normal (<i class="calibre6">on room air</i>) = “4 + age/4” or “2.5 + (0.2 × age)”</p>
<p class="noindent1">• Hypoxemia + nl A-a gradient: problem is ↓ P<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> or ↑ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> (ie, hypoventilation)</p>
<p class="noindent1">• Hypoxemia + ↑ A-a gradient: problem is either</p>
<p class="noindent2"><b class="calibre7">R</b> →<b class="calibre7"> L shunt</b>, anatomic (congenital heart dis) or severe pathophys (alveoli filled w/ fluid; eg, PNA, pulm edema); cannot overcome w/ 100% O<sub class="calibre10">2</sub> b/c of sigmoidal Hb-O<sub class="calibre10">2</sub> curve</p>
<p class="noindent2"><b class="calibre7">V/Q mismatch</b> where “shunt-like” areas (↓ V &amp; nl Q) cause unoxygenated blood to mix with oxygenated blood; can be overcome w/ ↑ O<sub class="calibre10">2</sub> delivery</p>
<p class="noindent2">Diffusion limitation: generally seen with exercise/↑CO</p>
<div class="cap">
<p class="caption"><a id="fig2-6" class="calibre4"></a><b class="calibre7">Figure 2-6</b> Workup of acute hypoxemia</p>
<p class="imagef1"><img src="../images/00047.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="noindent1">• <b class="calibre7">Cyanosis:</b> when &gt;5 g/dL of deoxygenated Hb in vessels of skin/mucous membranes. Central: ↓ S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> (pulm disease, shunt); abnl Hb [metHb, sulfHb, COHb (not true cyanosis)] Peripheral: ↓ blood flow → ↑ O<sub class="calibre10">2</sub> extraction (eg, ↓ CO, cold, arterial or venous obstruction)</p>
<p class="imaget"><img src="../images/00048.jpeg" alt="" class="calibre5"/></p>
<p class="noindent">CO binds to Hb more avidly than does O<sub class="calibre10">2</sub>. Pulse oximeter (Ox) misreads COHb as HbO<sub class="calibre10">2</sub> → falsely nl sat.</p>
<p class="noindent">Oxidizing drugs Δ Hb (ferrous) to MetHb (ferric), which cannot carry O<sub class="calibre10">2</sub>. Pulse ox misreads MetHb as HbO<sub class="calibre10">2</sub>.</p>
<p class="image1"><img src="../images/00049.jpeg" alt="" class="calibre5"/></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
<col class="calibre23"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="4"><p class="tbodyc"><b class="calibre7">Etiologies of High</b> ↑ <b class="calibre7">P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub></b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">“Won’t Breathe”</b></p></td>
<td class="th1" colspan="3"><p class="tbodyc"><b class="calibre7">“Can’t Breathe”</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">↓ <b class="calibre7">RR</b></p></td>
<td class="th1" colspan="2"><p class="tbodyc">↓ <b class="calibre7">V<sub class="calibre17">T</sub></b></p></td>
<td class="th1"><p class="tbodyc">↑ <b class="calibre7">V<sub class="calibre17">D</sub> and/or</b> ↓ <b class="calibre7">V<sub class="calibre17">T</sub></b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Respiratory Drive</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">NM System</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">CW/Pleura</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Lung/Airways</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc">Voluntary hypervent.</p>
<p class="tbodyc">Nl PI<sub class="calibre17">max</sub> &amp; A-a grad</p></td>
<td class="th1"><p class="tbodyc">↓ PI<sub class="calibre17">max</sub></p>
<p class="tbodyc">↓ PE<sub class="calibre17">max</sub></p></td>
<td class="th1"><p class="tbodyc">Abnl PEx</p>
<p class="tbodyc">Abnl CT</p></td>
<td class="th1"><p class="tbodyc">Abnl PFTs</p>
<p class="tbodyc">↓ End tidal CO<sub class="calibre17">2</sub></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">Metabolic alkalosis</b></p>
<p class="tbodyc"><b class="calibre7">1° neurologic:</b> brain-stem stroke, tumor, 1° alveolar hypovent</p>
<p class="tbodyc"><b class="calibre7">2° neurologic:</b> sedatives, CNS infxn, hypothyroidism</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Neuropathies:</b> cervical spine, phrenic nerve, GBS, ALS, polio</p>
<p class="tbodyc"><b class="calibre7">NMJ:</b> MG, LE</p>
<p class="tbodyc"><b class="calibre7">Myopathies:</b> diaphragm PM/DM, ↓ PO<sub class="calibre17">4</sub>, musc dystrophies</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Chest wall:</b> obesity,</p>
<p class="tbodyc">kyphosis,</p>
<p class="tbodyc">scoliosis</p>
<p class="tbodyc"><b class="calibre7">Pleura:</b> fibrosis effusion</p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">Lung parenchyma:</b> emphysema, ILD/fibrosis, CHF, PNA</p>
<p class="tbodyh"><b class="calibre7">Airways:</b> asthma, COPD, OSA, CF bronchiectasis</p></td>
</tr>
</tbody>
</table>
<p class="tfn">↑ VCO<sub class="calibre24">2</sub> typically transient cause of ↑ PaCO<sub class="calibre24">2</sub>; Ddx: exercise, fever, hyperthyroidism, ↑ work of breathing, ↑ carbs.</p>
<h2 class="ct"><a id="h35" class="calibre8"></a><a id="page_2-19" class="calibre8"></a><a href="part0003.html#rh40" class="calibre8">MECHANICAL VENTILATION</a></h2>
<p class="h">Indications</p>
<p class="noindent1">• Improve gas exchange: ↑ oxygenation, ↑ alveolar vent and/or reverse acute resp acidosis</p>
<p class="noindent1">• Relieve respiratory distress: ↓ work of breathing (can account for up to 50% of total O<sub class="calibre10">2</sub> consumption), ↓ respiratory muscle fatigue</p>
<p class="noindent1">• Apnea, airway protection, pulmonary toilet</p>
<p class="h1cr">S<small class="calibre31">UPPORTIVE</small> S<small class="calibre31">TRATEGIES</small> P<small class="calibre31">RIOR</small> <small class="calibre31">TO</small> I<small class="calibre31">NTUB</small>. <small class="calibre31">OR</small> A<small class="calibre31">FTER</small> E<small class="calibre31">XTUB</small>.</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre20"/>
<col class="calibre25"/>
<col class="calibre36"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="3"><p class="tbodyc"><b class="calibre7">Oxygen Delivery Systems</b> <span class="sm">(<i class="calibre6">Lancet</i> 2016;387:1867)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbodyc"><b class="calibre7">System or Device</b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">O<sub class="calibre17">2</sub> Flow<sup class="calibre27"><a id="fn50-a" class="calibre8"></a><a href="part0008.html#rfn50-a" class="calibre8">a</a></sup></b></p></td>
<td class="th1"><p class="tbodyc"><b class="calibre7">F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> Range &amp; Comments</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Low-flow nasal cannula</p></td>
<td class="th1"><p class="tbodyc">1–6</p></td>
<td class="th1"><p class="tbody">24–40%, 1L adds ~3% F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Standard face mask</p></td>
<td class="th1"><p class="tbodyc">5–10</p></td>
<td class="th1"><p class="tbody">35–50%, minimum 5 L/min</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Partial rebreather mask</p></td>
<td class="th1"><p class="tbodyc">&gt;10</p></td>
<td class="th1"><p class="tbody">40–70%</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Nonrebreather mask</p></td>
<td class="th1"><p class="tbodyc">&gt;10</p></td>
<td class="th1"><p class="tbody">60–80% (not 100% b/c air leaks)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">Air-entrainment mask</p>
<p class="tbody">(Venturi or Venti mask)</p></td>
<td class="th1"><p class="tbodyc">10–15<sup class="calibre27"><a id="fn50-b" class="calibre8"></a><a href="part0008.html#rfn50-b" class="calibre8">b</a></sup></p></td>
<td class="th1"><p class="tbody">24–50%, F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> stays constant</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody">High-flow nasal cannula (HFNC) <span class="sm">(<i class="calibre6">NEJM</i> 2015;372: 2185; <i class="calibre6">JAMA</i> 2015;313:2331 &amp; 2016;315:1354)</span></p></td>
<td class="th1"><p class="tbodyc">≤40</p></td>
<td class="th1"><p class="tbody">21–100%. In nonhypercapnic acute hypoxemic</p>
<p class="tbody">resp failure, ± ↓ intub. (espec if P<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub>/F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> ≤200) &amp; ↓ 90-d mort vs. stnd O<sub class="calibre17">2</sub> or NPPV.</p>
<p class="tbody">Routine use after extub. ↓ need for reintub</p></td>
</tr>
</tbody>
</table>
<p class="tfn"><sup class="calibre22"><a id="rfn50-a" class="calibre8"></a><a href="part0008.html#fn50-a" class="calibre8">a</a></sup>L/min. <sup class="calibre22"><a id="rfn50-b" class="calibre8"></a><a href="part0008.html#fn50-b" class="calibre8">b</a></sup>Total airflow &gt;60L/min. (Adapted from Marino P. <i class="calibre6">The ICU Book</i>, 4th ed, Philadelphia: LWW, 2014:431)</p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Noninvasive Positive Pressure Ventilation (NPPV)</b> <span class="sm">(<i class="calibre6">NEJM</i> 2015;372:e30)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Indications</b> <span class="sm">(<i class="calibre6">Lancet</i> 2009;374:250)</span></p></td>
<td class="th1"><p class="tbodyh"><i class="calibre6">Clinical:</i> mod–severe dyspnea, RR &gt;24–30, signs of ↑ work of breathing, accessory muscle use, abd paradox</p>
<p class="tbodyh"><i class="calibre6">Gas exchange:</i> P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> &gt;45 mmHg (&amp; significantly worse than -baseline), hypoxemia, P<sub class="calibre17">a</sub>O<sub class="calibre17">2</sub>/F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> &lt;200</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Contraindications</b></p>
<p class="tbodyh"><span class="sm">(<i class="calibre6">Crit Care Med</i> 2007;35:2402)</span></p></td>
<td class="th1"><p class="tbodyh">Claustrophobia, poor mask fit, Δ<b class="calibre7">MS</b>, vomiting, <b class="calibre7">cannot protect airway</b>, extrapulm organ failure, HD instab, sev UGIB, ↑ secretions</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Continuous positive airway pressure (CPAP)</b></p></td>
<td class="th1"><p class="tbodyh">≈ PEEP. Pt breathes spont. at own rate while vent maintains constant positive airway pressure throughout respiratory cycle.</p>
<p class="tbodyh">No limit on O<sub class="calibre17">2</sub> delivered (ie, can give hi-flow → F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> ≈1.0)</p>
<p class="tbodyh">Used if primary problem <b class="calibre7"><i class="calibre6">hypoxemia</i></b> (eg, CHF)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Bilevel positive airway pressure (BiPAP)</b></p></td>
<td class="th1"><p class="tbodyh">≈ PSV + PEEP. Able to set both inspiratory (usually 8–10 cm H<sub class="calibre17">2</sub>O) and expiratory pressures (usually &lt;5 cm H<sub class="calibre17">2</sub>O).</p>
<p class="tbodyh">Used if primary problem <i class="calibre6">hypoventilation</i>; F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> delivery limited</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Mask ventilation</b> (? helmet better; <span class="sm"><i class="calibre6">JAMA</i> 2016;315:2435</span>)</p></td>
<td class="th1"><p class="tbodyh">Tight-fitting mask connecting patient to a standard ventilator</p>
<p class="tbodyh">Can receive PS ~20–30 cm H<sub class="calibre17">2</sub>O, PEEP ~10 cm H<sub class="calibre17">2</sub>O, F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> ~1.0</p>
<p class="tbodyh">Used for short-term support (&lt;24 h) for a reversible process</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Conditions w/ strong evidence</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Cardiogenic pulmonary edema:</b> may ↓ intub. ± mortality <span class="sm">(<i class="calibre6">JAMA</i> 2005;294:3124; <i class="calibre6">Lancet</i> 2006;367:1155; <i class="calibre6">NEJM</i> 2008;359:142)</span></p>
<p class="tbodyh"><b class="calibre7">COPD exac.</b> w/ ↑ P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub>: ↓ intub. &amp; mort., but if pH &lt;7.3 → intubate</p>
<p class="tbodyh">Acute hypoxemic resp failure: ↓ intub. &amp; mortality <span class="sm">(<i class="calibre6">JAMA</i> 2020;324:57)</span></p>
<p class="tbodyh">High-risk extub. (age &gt;65, CHF, APACHE II &gt;12): NPPV × 24 h directly after extub. → ↓ reintub. and, if P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> &gt;45 mmHg during SBT, ↓ mortality. Does not Δ total # vent days <span class="sm">(<i class="calibre6">JAMA</i> 2018;320:1881)</span>.</p>
<p class="tbodyh">Hypoxemic resp failure after abdominal surgery: ↓ reintubation</p>
<p class="tbodyh"><b class="calibre7">Immunosupp.</b> w/ infiltrates: ↓ complications &amp; mortality</p></td>
</tr>
</tbody>
</table>
<p class="h1cr">V<small class="calibre31">ENTILATOR</small> M<small class="calibre31">ANAGEMENT</small></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Ventilator Modes and Principles</b> <span class="sm">(<i class="calibre6">NEJM</i> 2001;344:1986; <i class="calibre6">Chest</i> 2015;148:340)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cont mandatory ventilation (CMV), aka Assist control (AC)</b></p></td>
<td class="th1"><p class="tbodyh">Vent delivers a minimum number of supported breaths</p>
<p class="tbodyh">Additional Pt-initiated breaths trigger <i class="calibre6">fully assisted</i> vent breaths</p>
<p class="tbodyh">∴ Vent-triggered breaths identical to Pt-triggered breaths</p>
<p class="tbodyh">Tachypnea → ? resp. alkalosis, breath-stacking, &amp; auto-PEEP</p>
<p class="tbodyh">May be pressure targeted or volume targeted (qv)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pressure support</b></p>
<p class="tbodyh"><b class="calibre7">vent (PSV)</b></p></td>
<td class="th1"><p class="tbodyh">Support Pt-initiated breaths w/ a set inspiratory pressure &amp; PEEP</p>
<p class="tbodyh">A mode of <i class="calibre6">partial</i> vent support because no set rate</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Other</b></p></td>
<td class="th1"><p class="tbodyh">Synch intermittent mand. vent: deliver min # supported breaths; V<sub class="calibre17">T</sub> of additional Pt-initiated breaths determined by Pt’s effort</p>
<p class="tbodyh">Proportional assist ventilation (PAV): delivers variable pressure to achieve targeted % of work of breathing</p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><a id="page_2-20" class="calibre4"></a><p class="tbodyc"><b class="calibre7">Volume or Pressure Targeted</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Volume targeted</b></p></td>
<td class="th1"><p class="tbodyh">Vent delivers a set V<sub class="calibre17">T</sub>; pressures depend on airway resist. &amp; lung/CW compl.</p>
<p class="tbodyh"><b class="calibre7">Benefit:</b> ↑ control over ventilation (ideal initial ventilator setting); benefit in ALI/ARDS; easy to measure mechanics (PIP, P<sub class="calibre17">plat</sub>, airway resist., compl.)</p>
<p class="tbodyh">Volume control (VC) ⊕: vent delivers variable pressure (depending on real- time lung compliance) to achieve set V<sub class="calibre17">T</sub></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Pressure</b></p>
<p class="tbody"><b class="calibre7">targeted</b></p></td>
<td class="th1"><p class="tbodyh">Vent delivers a fixed inspiratory pressure regardless of V<sub class="calibre17">T</sub></p>
<p class="tbodyh">V<sub class="calibre17">T</sub> depends on airway resistance and lung/chest wall compliance</p>
<p class="tbodyh"><b class="calibre7">Benefit:</b> may ↑ Pt comfort (PSV) requiring less sedation</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">General</b></p>
<p class="tbody"><b class="calibre7">principles</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Institutional/practitioner preference</b> and <b class="calibre7">Pt comfort</b> usually dictate ventilator strategy; no strategy has proven superior</p>
<p class="tbodyh"><b class="calibre7">Alarms</b> can be set for ↓ or ↑ volumes and ↑ airway pressures in pressure- targeted and volume-targeted strategies, respectively</p>
<p class="tbodyh"><b class="calibre7">Risks:</b> volutrauma (ie, overdistention, if set volume too high; <span class="sm"><i class="calibre6">NEJM</i> 2013;369:2126</span>), barotrauma [can happen w/ relatively high set volumes (espec if stiff lungs) or if pressure target set too high; key is to monitor transpulmonary pressure (difference between P<sub class="calibre17">plat</sub> and esophageal ≈ intrapleural), not just airway pressure]; can result in PTX, pneumomediastinum</p>
<p class="tbodyh"><b class="calibre7">Hypo-/hyperventilation:</b> need to ✓ minute vent &amp; pH/P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub></p></td>
</tr>
</tbody>
</table>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Variables on the Ventilator</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub></b></p></td>
<td class="th1"><p class="tbodyh">Fraction of inspired air that is oxygen</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">V<sub class="calibre17">T</sub></b> (tidal vol)</p></td>
<td class="th1"><p class="tbodyh">Volume of breath delivered; lung-protective ventilation: goal ≤6 mL/kg IBW</p>
<p class="tbodyh">If no ARDS, similar # of vent days at higher V<sub class="calibre17">T</sub> <span class="sm">(<i class="calibre6">JAMA</i> 2018;320:1872)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">f</b> (resp. rate)</p></td>
<td class="th1"><p class="tbodyh">Rate set by ventilator, f may be lower than RR if Pt triggering breaths.</p>
<p class="tbodyh">Adjust to achieve desired P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub>.</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Positive end- expiratory pressure (PEEP)</b></p></td>
<td class="th1"><p class="tbodyh">Positive pressure applied during exhalation via resistor in exhalation port</p>
<p class="tbodyh">Benefits: prevents alveolar collapse, ↓ shunt, ↑ O<sub class="calibre17">2</sub> via alveolar recruitment and improved compliance, allows severely obstructed Pt to initiate breath</p>
<p class="tbodyh">Cardiac effects: ↓ preload by ↑ intrathoracic pressure → ↓ venous return; ↓ afterload by ↓ cardiac transmural pressure; may ↑ or ↓ CO and may ↑ or ↓ oxygen delivery based on the above</p>
<p class="tbodyh">Auto-PEEP or intrinsic PEEP (iPEEP): inadeq. exhalation time → lungs unable to completely empty before next breath (ie, “breath stacking”); if flow at end-expiration, there must be pressure = auto-PEEP. Will ↓ preload and may ↓ CO, espec if hypovolemic</p>
<p class="tbodyh1">Will ↑ work of breathing as must be overcome by Pt to trigger breaths; can prevent Pt from triggering ventilator, extrinsic PEEP helps</p>
<p class="tbodyh1">Can be detected if end-expiratory flow ≠ 0 before next breath</p>
<p class="tbodyh1">Can measure by occluding expiratory port of vent at end-expiration</p>
<p class="tbodyh1">Can ↓ by: ↑ exp time, ↓ RR, ↓ V<sub class="calibre17">T</sub>, Rx bronchospasm and secretions</p>
<p class="tbodyh1">If iPEEP &gt;set PEEP, minimize iPEEP, then set PEEP to ~80% of iPEEP to ↓ ineffective triggering</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Inspiratory time</b></p></td>
<td class="th1"><p class="tbody">Normally I:E ratio is ~1:2; however, can alter I time (and consequently flow rate, see later); use in pressure-control mode</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Inspiratory flow rates</b></p></td>
<td class="th1"><p class="tbody">↑ flow rate → ↓ I time → ↑ E time → ∴ may improve ventilation in obstructive disease, but may affect resp rate and bronchodilation/constriction</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Peak inspiratory pressure (PIP)</b></p></td>
<td class="th1"><p class="tbody">Dynamic measurement during inspiration; set in pressure-targeted mode</p>
<p class="tbody">Determined by airway resistance and lung/chest wall compliance</p>
<p class="tbody">↑ PIP w/o ↑ P<sub class="calibre17">plat</sub> → ↑ airway resist (eg, bronchospasm, plugging)</p>
<p class="tbody">↓ PIP → ↓ airway resistance or air leak in the system</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Plateau pressure (P<sub class="calibre17">plat</sub>)</b></p></td>
<td class="th1"><p class="tbody">Static measurement at the end of inspiration when there is no flow</p>
<p class="tbody">Determined by resp system compliance (resist. not a factor since no flow)</p>
<p class="tbody">↑ P<sub class="calibre17">plat</sub> → ↓ lung or chest wall compliance (eg, PTX, pulmonary edema, pneumonia, atelectasis), ↑ PEEP or auto-PEEP</p>
<p class="tbody">P<sub class="calibre17">plat</sub> &lt;30 cm H<sub class="calibre17">2</sub>O ↓ barotrauma (↓ V<sub class="calibre17">T</sub>, ↓ PEEP or ↑ compl [eg, by diuresis])</p></td>
</tr>
</tbody>
</table>
<p class="h">Tailoring the ventilator settings</p>
<p class="noindent1">• To improve oxygenation: options include ↑ F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub>, ↑ PEEP</p>
<p class="noindent2">S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> 88–92% acceptable <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2016;193:43)</span>, do not exceed 96% <span class="r1">(</span><span class="r2">BMJ</span> <span class="r1">2018;363:k4169)</span></p>
<p class="noindent2">First, ↑ F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub>. If &gt;0.6 and oxygenation remains suboptimal, then try ↑ PEEP:</p>
<p class="noindent2">If ↑ P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> <i class="calibre6">and</i> P<sub class="calibre10">plat</sub> stable, suggests recruitable lung (ie, atelectasis). If PEEP 20 &amp; F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> 1.0 and oxygenation remains suboptimal, consider rescue/expt strategies  (see “ARDS”).</p>
<p class="noindent2"><a id="page_2-21" class="calibre4"></a>If ↑ PEEP yields no Δ <i class="calibre6">or</i> ↓ P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> <i class="calibre6">or</i> ↑ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub>, suggests additional lung <i class="calibre6">not</i> recruitable and instead overdistending lung → ↑ shunt &amp; dead space; ∴ ↓ PEEP</p>
<p class="noindent2">If no ARDS, PEEP ≤5 (&amp; S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> &gt;92%) noninferior to PEEP 8 <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2020;324:2509)</span></p>
<p class="noindent1">• To improve ventilation: ↑ V<sub class="calibre10">T</sub> or inspiratory pressure, ↑ RR (may need to ↓ I time). Nb, tolerate ↑ P<sub class="calibre10">a</sub>CO<sub class="calibre10">2</sub> (permissive hypercapnia) in ALI/ARDS (qv) as long as pH &gt;7.2.</p>
<p class="h">Acute ventilatory deterioration (usually ↑ PIP)</p>
<p class="noindent1">• Response to ↑ PIP: disconnect Pt from vent, bag, auscultate, suction, ✓ CXR &amp; ABG</p>
<div class="cap">
<p class="caption"><a id="fig2-7" class="calibre4"></a><b class="calibre7">Figure 2-7</b> Approach to acute ventilatory deterioration</p>
<p class="imagef1"><img src="../images/00050.jpeg" alt="" class="calibre5"/></p>
</div>
<p class="tfn">(Adapted from Marino PL. <i class="calibre6">The ICU Book</i>, 4th ed., Philadelphia: LWW, 2014)</p>
<p class="h">Liberating from the ventilator <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2012;367:2233;</span> <span class="r2">Lancet</span> <span class="r1">2016;387:1856)</span></p>
<p class="noindent1">• Perform daily assessment of readiness for spontaneous breathing trial (SBT)</p>
<p class="noindent1">• Clinical screening criteria: VS stable, minimal secretions, adequate cough, cause of respiratory failure or previously failed SBT reversed</p>
<p class="noindent1">• Vent parameters: P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> &gt;200, PEEP ≤5, f/V<sub class="calibre10">T</sub> &lt;105, V<sub class="calibre10">E</sub> &lt;12 L/min, VC &gt;10 mL/kg; rapid shallow breathing index (f/V<sub class="calibre10">T</sub>) &gt;105 predicts failure, NPV 0.95 <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">1991;324:1445)</span></p>
<p class="noindent1">• Daily awakening trial (d/c all sedation; <span class="r2">Lancet</span> <span class="r1">2008;371:126</span>): open eyes &amp; w/o: agitation, RR &gt;35, S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> &lt;88%, resp distress or arrhythmias (if fail, restart sedation at ½ prior dose)</p>
<p class="noindent1">• SBT = CPAP × 30 min superior to T-piece × 120 min <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;321:2175)</span> failure if: deteriorating ABGs, ↑ RR, ↑ or ↓ HR, ↑ or ↓ BP, diaphoresis, anxiety</p>
<p class="noindent1">• Tolerate SBT → extubation. Fail SBT → ? cause → work to correct → retry SBT qd</p>
<p class="noindent1">• If high-risk, extubate to either NPPV or NPPV alternating w/ HFNC <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;322:1465)</span></p>
<p class="noindent1">• ? acetazolamide in Pts w/ COPD &amp; metabolic alkalosis <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:480)</span></p>
<p class="h">Complications</p>
<p class="noindent1">• Oxygen toxicity (theoretical); proportional to duration + degree of ↑ oxygen (F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> &gt;0.6)</p>
<p class="noindent1">• Ventilator-induced lung injury (see “ARDS”)</p>
<p class="noindent1">• Ventilator-associated pneumonia (~1%/d, mortality rate ~30%)</p>
<p class="noindent2">typical pathogens: MRSA, <i class="calibre6">Pseudomonas</i>, <i class="calibre6">Acinetobacter</i> and <i class="calibre6">Enterobacter</i> species</p>
<p class="noindent2">preventive strategies <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2005;171:388)</span>: wash hands, HOB elevated, non-nasal intub., enteral nutrition rather than TPN?, routine suction of subglottic secretions, avoid unnecessary abx &amp; transfusions; routine oral antiseptic controversial</p>
<p class="noindent1">• Stress ulcers/GIB: prophylaxis w/ PPI ↓ GIB, but no ∆ in overall course <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;379:2199)</span></p>
<p class="noindent1">• Laryngeal</p>
<p class="noindent2">edema: for Pts vent &gt;36 h; ? predicted by ⊕ cuff leak test. Methylprednisolone 20 mg IV q4h starting 12 h pre-extub. → ↓↓ edema and 50% ↓ in reintubation <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2007;369:1003)</span>.</p>
<p class="noindent2">ulceration: consider <i class="calibre6">tracheostomy</i> for Pts in whom expect &gt;14 d of mech vent → ↓ duration mech vent, ↓ # ICU days <span class="r1">(</span><span class="r2">BMJ</span> <span class="r1">2005;330:1243)</span>; no benefit to performing at ~1 wk vs. waiting until ~2 wk <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2010;303:1483)</span></p>
<p class="noindent1">• Malnutrition (for all critically ill Pts): <i class="calibre6">enteral nutrition</i> initiated early is safe but not necessary <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2012;307:795)</span>, but bolus may ↑ risk of VAP &amp; <i class="calibre6">C diff.</i> <span class="r1">(</span><span class="r2">JPEN</span> <span class="r1">2002;26:174)</span>; no clear benefit to ✓ing gastric residuals <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2013;309:249)</span>; permissive enteral underfeeding (~½ of calculated caloric req) &amp; standard enteral feeding w/ similar outcomes <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:2398)</span>; <i class="calibre6">parenteral nutrition</i> should be delayed until after day 8 to ↓ risk of infections, cholestasis, RRT, ventilator days <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;365:506)</span></p>
<p class="noindent1">• Oversedation/delirium: BDZs and polypharmacy are risk factors</p>
<p class="noindent2">propofol: HoTN in ~25%; <i class="calibre6">propofol infusion syndrome</i> (PRIS) ? espec w/ high (&gt;5 mg/kg/h) &amp; prolonged (&gt;48 h) infusions &amp; concom vasopressors → ↑ AG, cardiac dysfxn, rhabdomyolysis, ↑ triglycerides, &amp; renal failure <span class="r1">(</span><span class="r2">Crit Care</span> <span class="r1">2009;13:R169)</span></p>
<p class="noindent2">dexmedetomidine: no benefit on vent-free days <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:1460 &amp; 2017;317:1321);</span> similar outcomes to propofol when utilized as sole agent <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:1424)</span></p>
<h2 class="ct"><a id="h36" class="calibre8"></a><a id="page_2-22" class="calibre8"></a><a href="part0003.html#rh41" class="calibre8">ACUTE RESPIRATORY DISTRESS SYNDROME</a></h2>
<p class="h">Berlin definition <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2012;307:2526)</span></p>
<p class="noindent1">• Acute onset within 1 week of clinical insult or worsening respiratory status</p>
<p class="noindent1">• Bilateral infiltrates without alternative explanation (eg, effusion, atelectasis, nodules)</p>
<p class="noindent1">• Edema not fully explained by fluid overload or congestive heart failure</p>
<p class="noindent1">• Hypoxemia: P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> determined with 5 cm H<sub class="calibre10">2</sub>O of PEEP</p>
<p class="noindent2">P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> 200–300 = mild ARDS (may be on NPPV), 100–200 = mod, &lt;100 = severe</p>
<p class="h">Pathophysiology <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2016;388:2416)</span></p>
<p class="noindent1">• ↑ intrapulmonary shunt → hypoxemia (∴ Rx w/ PEEP to prevent derecruitment)</p>
<p class="noindent1">• ↑ increased dead space fraction (see Appendix), predicts ↑ mort <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2002;346:1281)</span></p>
<p class="noindent1">• ↓ compliance: V<sub class="calibre10">T</sub>/(P<sub class="calibre10">plat</sub> – PEEP) &lt;50 mL/cm H<sub class="calibre10">2</sub>O</p>
<p class="h">Pathology</p>
<p class="noindent1">• Diffuse alveolar damage (DAD) seen in 40% of autopsies <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2013;187:761)</span></p>
<p class="noindent1">• If no clear inciting event and ILD considered as alt dx, consider bx <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2015;148:1073)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre26"/>
<col class="calibre26"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Etiologies</b></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Direct Injury</b></p></td>
<td class="th1"><p class="tbodyh"><b class="calibre7">Indirect Injury</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1">
<p class="tnl"><span class="tft">•</span> Pneumonia (~40%)</p>
<p class="tnl"><span class="tft">•</span> Aspiration (~15%)</p>
<p class="tnl"><span class="tft">•</span> Near drowning</p>
<p class="tnl"><span class="tft">•</span> Inhalation injury</p>
<p class="tnl"><span class="tft">•</span> Lung contusion</p></td>
<td class="th1">
<p class="tnl"><span class="tft">•</span>Sepsis (~25%)</p>
<p class="tnl"><span class="tft">•</span>Shock</p>
<p class="tnl"><span class="tft">•</span>DIC</p>
<p class="tnl"><span class="tft">•</span>Pancreatitis</p>
<p class="tnl"><span class="tft">•</span>Trauma/multiple fractures</p>
<p class="tnl"><span class="tft">•</span>Transfusion (TRALI)</p></td>
</tr>
</tbody>
</table>
<p class="h">Treatment <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2021;398:622)</span></p>
<p class="noindent1">• Goal is to maintain gas exchange, sustain life, &amp; avoid ventilator-induced lung injury (VILI)</p>
<p class="noindent1">• In Pts on O<sub class="calibre10">2</sub> for COVID-19 PNA, dexamethasone ↓ 28-day mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2021;384:693)</span></p>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre18"/>
<col class="calibre13"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbodyc"><b class="calibre7">Mechanisms of VILI</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">Ventilator Strategies</b> (see <a href="http://ARDSnet.org" class="calibre4">ARDSnet.org</a>)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Barotrauma/volutrauma:</b> alveolar dist → mech damage</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">V<sub class="calibre17">T</sub></b> ≤<b class="calibre7">6 mL/kg, P<sub class="calibre17">plat</sub></b> ≤<b class="calibre7">30 cm H<sub class="calibre17">2</sub>O</b>, tolerate ↑ P<sub class="calibre17">a</sub>CO<sub class="calibre17">2</sub> (but keep pH &gt;7.2), ↓ mortality <span class="sm">(<i class="calibre6">NEJM</i> 2000;342:1301)</span></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Biotrauma</b> → SIRS</p></td>
<td class="th1"><p class="tbody">Low V<sub class="calibre17">T</sub>, open lung strategy w/ high PEEP</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Atelectrauma:</b> repetitive alveoli recruit &amp; decruit</p></td>
<td class="th1"><p class="tbody"><b class="calibre7">Titrate PEEP to prevent tidal alveolar collapse</b></p>
<p class="tbody">See below for options</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Hyperoxia:</b> ? injury; worsened V/Q matching</p></td>
<td class="th1"><p class="tbody">↑ <b class="calibre7">PEEP</b> rather than F<sub class="calibre17">i</sub>O<sub class="calibre17">2</sub> (keep &lt;0.60)</p>
<p class="tbody">O<sub class="calibre17">2</sub>-induced injury only theoretical in humans</p></td>
</tr>
</tbody>
</table>
<p class="h">The 6 Ps</p>
<p class="noindent1">• <b class="calibre7">PEEP</b> (see below)</p>
<p class="noindent1">• <b class="calibre7">Proning:</b> if P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub> &lt;150, prone positioning ≥16 h ↓ mort ~50% <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2013;368:2159)</span></p>
<p class="noindent1">• <b class="calibre7">Paralysis:</b> no benefit routinely <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2019;380:1997)</span>; consider if Pt-vent dyssynchrony</p>
<p class="noindent1">• <b class="calibre7">Peeing (fluid balance):</b> target CVP 4–6 cm H<sub class="calibre10">2</sub>O (if nonoliguric &amp; normotensive) → ↑ vent/ICU-free days, but no Δ mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;354:2564)</span>; PA catheter unproven <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;354:2213)</span>; consider BNP &gt;200 to trigger diuresis (UOP goal 4.5–9 mL/kg/h × 3 h)</p>
<p class="noindent1">• <b class="calibre7">Pulm vasodilators:</b> inhaled NO or prostacyclins ↑ P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub>/F<sub class="calibre10">i</sub>O<sub class="calibre10">2;</sub> no ↓ mort or vent-free days <span class="r1">(</span><span class="r2">BMJ</span> <span class="r1">2007;334:779)</span></p>
<p class="noindent1">• <b class="calibre7">Perfusion (V-V ECMO):</b> may be useful if refractory <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:1965)</span></p>
<p class="h">PEEP titration methods <span class="r">(best method unclear)</span></p>
<p class="noindent1">• No benefit at given V<sub class="calibre10">T</sub> if titrated to P<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> alone <span class="r1">(</span><span class="r2">NEJM</span><span class="r1"> 2004;351:327;</span> <span class="r2">JAMA</span><span class="r1"> 2008;299:637)</span></p>
<p class="noindent1">• Best PEEP trial: incremental PEEP titration using compliance, O<sub class="calibre10">2</sub>, hemodynamics</p>
<p class="noindent2">If able to ↑ PEEP w/o ↑ P<sub class="calibre10">plat</sub>, suggests “recruitability”</p>
<p class="noindent2">∴↑ PEEP if → ↑ S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> (target ≥88–90%) &amp; P<sub class="calibre10">plat</sub> ≤30 cm H<sub class="calibre10">2</sub>O → ↓ time on vent, better lung mechanics <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2008;299:646)</span>, ? ↓ mortality <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2010;303:865)</span></p>
<p class="noindent1">• ARDSnet “high” PEEP table for optimal F<sub class="calibre10">i</sub>O<sub class="calibre10">2</sub>/PEEP combo for goal S<sub class="calibre10">a</sub>O<sub class="calibre10">2</sub> (<a href="http://ARDSnet.org" class="calibre4">ARDSnet.org</a>)</p>
<p class="noindent1">• Recruitment maneuvers: stepwise preferred over sustained inflation, evidence insufficient to recommend routine use <span class="r1">(</span><span class="r2">Resp Care</span> <span class="r1">2015;60:1688)</span>; recruitment maneuvers at high pressures ? ↑ mortality <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2017;318:1335</span><span class="r2">)</span></p>
<p class="noindent1">• Esophageal balloon: used to estimate pleural pressure and thereby estimate trans-pulmonary pressure (ie, true airway distending pressure). Adjusting PEEP according to esoph pressure to maintain optimal transpulm. pressure does not ∆ ventilator-free days or mortality, although does ↓ need for advanced rescue Rx (see above) <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;321:846)</span>.</p>
<p class="noindent1">• Driving pressure (ΔP = P<sub class="calibre10">plateau</sub>–PEEP): ↓ ΔP a/w ↑ survival; target &lt;15 <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2015;372:747)</span></p>
<p class="h">Prognosis <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;315:788)</span></p>
<p class="noindent1">• Mortality ~40% overall in clinical trials; 9–15% resp. causes, 85–91% extrapulm (MODS)</p>
<p class="noindent1">• Survivors: PFTs ~normal, ↓ D<sub class="calibre10">L</sub>CO, muscle wasting, weakness persists <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2003;348:683)</span>, ↓ exercise tolerance, ↓ QoL, ↑ psych morbidity <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2011;364:1293)</span>; 44% of previously employed Pts jobless at 12 mos <span class="r1">(</span><span class="r2">AJRCCM</span> <span class="r1">2017;196:1012)</span></p>
<h2 class="ct"><a id="h37" class="calibre8"></a><a id="page_2-23" class="calibre8"></a><a href="part0003.html#rh42" class="calibre8">SEPSIS AND SHOCK</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre23"/>
<col class="calibre35"/>
</colgroup>
<thead class="calibre14">
<tr class="calibre15">
<td class="th" colspan="2"><p class="tbodyc"><b class="calibre7">Definitions</b> <span class="sm">(<i class="calibre6">JAMA</i> 2016;315:801; 2017;317:290 &amp; 301)</span></p></td>
</tr>
</thead>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Sepsis</b></p></td>
<td class="th1"><p class="tbody">Life-threatening organ dysfxn (SOFA ≥2) due to infection</p>
<p class="tbody">Quick SOFA (qSOFA): ≥2 of the following: RR ≥22, ΔMS, SBP ≤100 mmHg</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Septic shock</b></p></td>
<td class="th1"><p class="tbody">Sepsis-induced circulatory and cellular/metabolic abnormalities severe enough to ↑ mortality; hypotension requiring pressors for MAP ≥65 and lactate &gt;2 despite adequate fluid resuscitation</p></td>
</tr>
<tr class="calibre15">
<td class="th1" colspan="2"><p class="tbody"><b class="calibre7">Sequential Organ Failure Assessment (SOFA):</b> ↑ points for worsening organ dysfxn: respiration (↓ P:F ratio); coag (↓ plt); liver (↑ bili); CV (↓ MAP or ↑ pressors); CNS (↓ GCS); renal (↑ Cr or ↓ UOP)</p></td>
</tr>
</tbody>
</table>
<p class="h">Shock <span class="r">(see “PA Catheter &amp; Tailored Therapy” for subtypes;</span> <span class="r2">NEJM</span> <span class="r1">2013;369:1726</span><span class="r">)</span></p>
<p class="noindent1">• Tissue hypoxia due to ↓ tissue perfusion and hence ↓ tissue O<sub class="calibre10">2</sub> delivery and/or ↑ O<sub class="calibre10">2</sub> consumption or inadequate O<sub class="calibre10">2</sub> utilization</p>
<p class="noindent1">• Typical signs include HoTN (SBP &lt;90 mmHg or drop in SBP &gt;40 mmHg), tachycardia, oliguria (UOP &lt;0.5 cc/kg/h), Δ mentation, metabolic acidosis ± ↑ lactate</p>
<p class="noindent1">• Hard to dx as ↑ SVR can maintain SBP, but tissue perfusion poor; shock index (HR/SBP) &gt;0.9 and pulse pressure [(SBP – DBP)/SBP] &lt;25% clues to significant shock</p>
<p class="h1cr">M<small class="calibre31">ANAGEMENT</small> <span class="r3">(</span><span class="r4">Crit Care Med</span> <span class="r3">2021;49:e1063)</span></p>
<p class="h">Fluids</p>
<p class="noindent1">• Aggressive IV fluid resuscitation (30 mL/kg) admin in boluses w/in 3 h of presentation</p>
<p class="noindent1">• Crystalloid as good as colloid for resuscitation <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2013;310:1809;</span> <span class="r2">NEJM</span> <span class="r1">2014;370:1412)</span></p>
<p class="noindent1">• No consistently seen benefit of balanced crystalloid (LR, Plasma-Lyte) vs. NS in terms of mortality, organ failure or need for RRT <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018;378:829 &amp; 2022:386:815)</span></p>
<p class="noindent1">• NaHCO<sub class="calibre10">3</sub> may ↓ mortality &amp; need for RRT if AKI &amp; pH &lt;7.2 <span class="r1">(</span><span class="r2">Lancet</span> <span class="r1">2018;392:31)</span></p>
<p class="noindent1">• Predictors of fluid responsiveness: pulse pressure variation &gt;13% w/ respiration <span class="r1">(</span><span class="r2">Chest</span> <span class="r1">2008;133:252)</span>; resp. variation in IVC diam, or &gt;10% ↑ in pulse pressure w/ passive leg raise. Static CVP poor surrogate.</p>
<p class="noindent1">• After early resuscitation, if ALI/ARDS, target CVP 4–6 mmHg because additional fluids may be harmful → ↑ ventilator/ICU days <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2006;354:2564;</span> <span class="r2">Chest</span> <span class="r1">2008;133:252)</span></p>
<p class="h">Pressors &amp; inotropes<span class="r"> (also see “ICU Medications”)</span></p>
<p class="noindent1">• MAP target 65 mmHg as good as 80–85 and ↓ AF <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2014;370:1583;</span> <span class="r2">JAMA</span> <span class="r1">2020;323:938)</span></p>
<p class="noindent1">• Norepinephrine: ↓ arrhythmia &amp; mortality c/w dopamine <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2010;362:779;</span> <span class="r2">Crit Care Med</span> <span class="r1">2012;40:725)</span> and ∴ is pressor of choice in septic shock</p>
<p class="noindent1">• Vasopressin: adding to norepi (vs. using high-dose norepi) ↓ risk of AF &amp; RRT by ~¼ <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2018;319:1889)</span></p>
<p class="noindent1">• If refractory vasoplegia: angiotensin II (Giaprezza), methylene blue, steroids (vide infra)</p>
<p class="noindent1">• If targets (see below) not reached after adequate fluids and pressors, consider inotropes</p>
<p class="h">Targets</p>
<p class="noindent1">• Lactate clearance (≥20%/2 h) as effective as S<sub class="calibre10">cv</sub>O<sub class="calibre10">2</sub> to guide resusc. <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2010;303:739)</span></p>
<p class="noindent1">• Targeting capillary refill time ≤3 sec (check q30min) as good if not better than lactate clearance <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2019;321:654)</span></p>
<p class="h">Antibiotics</p>
<p class="noindent1">• Start empiric IV abx as soon as possible after recognition of severe sepsis or septic shock; every hr delay in abx admin a/w 7.6% ↑ in mortality <span class="r1">(</span><span class="r2">Crit Care Med</span> <span class="r1">2006;34:1589)</span>, abx admin w/in 3 h of presentation in the ED a/w ↓ in-hospital mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017;376:2235)</span></p>
<p class="noindent1">• If possible, obtain 2 sets of BCx before urgently starting abx (but do not delay abx)</p>
<p class="noindent1">• Broad gram-positive (incl MRSA) &amp; gram-neg (incl highly resistant) coverage, ± anaerobes</p>
<p class="noindent1">• Procalcitonin-guided <i class="calibre6">cessation</i> (not initiation) ↓ mortality <span class="r1">(</span><span class="r2">Crit Care Med</span> <span class="r1">2018;46:684)</span></p>
<p class="noindent1">• Empiric micafungin in critically ill Pts w/ Candida colonization &amp; sepsis of unknown etiology ↓ invasive fungal infxns &amp; tended ↑ invasive fungal infxn-free survival, espec. in Pts w/ 1,3-b-D-glucan &gt;80 <span class="r1">(</span><span class="r2">JAMA</span> <span class="r1">2016;316:1555)</span></p>
<p class="h">Steroids <span class="r1">(</span><span class="r2">Crit Care Med</span> <span class="r1">2018;46:1411)</span></p>
<p class="noindent1">• Hydrocortisone 50 mg IV q6 + fludrocortisone 50 µg via NGT daily in septic shock ↓ duration of shock and may ↓ mortality <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2018; 378:797 &amp; 809)</span></p>
<p class="noindent1">• Consider in Pts w/ refractory shock on escalating doses of pressors</p>
<p class="h">Early Goal-Directed Therapy <span class="r">(EGDT)</span></p>
<p class="noindent1">• Historically: IVF &amp; pressors for MAP ≥65 mmHg, CVP 8–12 mmHg, UOP ≥0.5 mL/kg/h; inotropes &amp; PRBCs for S<sub class="calibre10">cv</sub>O<sub class="calibre10">2</sub> ≥70% in 6 h <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2001;345:1368)</span></p>
<p class="noindent1">• However, now in era of early abx and adequate fluid resuscitation, no ↓ in mortality w/ EGDT vs. current usual care, and ↑ hospital costs <span class="r1">(</span><span class="r2">NEJM</span> <span class="r1">2017; 376:2223)</span></p>
<h2 class="ct"><a id="h38" class="calibre8"></a><a id="page_2-24" class="calibre8"></a><a href="part0003.html#rh43" class="calibre8">TOXICOLOGY</a></h2>
<table class="tabb">
<colgroup class="calibre11">
<col class="calibre30"/>
<col class="calibre30"/>
<col class="calibre37"/>
</colgroup>
<tbody class="calibre16">
<tr class="calibre15">
<td class="th"><p class="tbodyc"><b class="calibre7">Drug/Toxin</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">Signs/Sx and Diagnostics</b></p></td>
<td class="th"><p class="tbodyc"><b class="calibre7">Management Options</b></p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Acetaminophen</b></p></td>
<td class="th1"><p class="tbody">Vomiting, ↑ AG &amp; nl OG metabolic acidosis, hepatitis &amp; hepatic failure, renal failure</p></td>
<td class="th1"><p class="tbody">N-acetylcysteine (NAC) infusion</p>
<p class="tbody">Hemodialysis if massive O/D</p>
<p class="tbody">See “Acute liver failure”</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Salicylates</b></p></td>
<td class="th1"><p class="tbody">Tinnitus, hyperventilation, abd. pain, vomiting, ΔMS, mixed ↑ AG &amp; nl OG metabolic acidosis + respiratory alkalosis</p></td>
<td class="th1"><p class="tbody">IVF resuscitation</p>
<p class="tbody">Alkalinization w/ NaHCO<sub class="calibre17">3</sub></p>
<p class="tbody">Maintain respiratory alkalemia</p>
<p class="tbody">Consider hemodialysis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Opioids</b></p></td>
<td class="th1"><p class="tbody">↓ mentation, ↓ RR, miosis</p></td>
<td class="th1"><p class="tbody">IV naloxone</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Benzodiazepines</b></p></td>
<td class="th1"><p class="tbody">↓ mentation, ataxia, ↓ RR</p></td>
<td class="th1"><p class="tbody">Flumazenil <i class="calibre6">not</i> rec (can precipitate withdrawal/seizures)</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Calcium channel blockers</b></p></td>
<td class="th1"><p class="tbody">Bradycardia, AV block, hypotension, HF, hyperglycemia</p></td>
<td class="th1"><p class="tbody">IVF, vasopressors, Ca infusion, hyperinsulinemic euglycemia,</p>
<p class="tbody">? intralipid emulsion, pacing</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Beta blockers</b></p></td>
<td class="th1"><p class="tbody">Bradycardia, AV block, hypotension, HF, hypoglycemia</p></td>
<td class="th1"><p class="tbody">Glucagon, vasopressors, pacing</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Digoxin</b></p></td>
<td class="th1"><p class="tbody">N/V, bradycardia, AV block, delirium, xanthopsia</p>
<p class="tbody">✓ serum dig level (but may be inaccurate if &lt;6 h since last dose), renal function</p></td>
<td class="th1"><p class="tbody">Correct hypokalemia</p>
<p class="tbody">Digibind if hyperkalemia, life- threatening dysrhythmia</p>
<p class="tbody">Consider hemodialysis</p>
<p class="tbody">Lidocaine for arrhythmias</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Tricyclic antidepressants</b></p></td>
<td class="th1"><p class="tbody">Hypotension, seizures, arrhythmia, ↑ QRS, ↑ QT</p></td>
<td class="th1"><p class="tbody">IVF resuscitation, IV sodium bicarbonate, vasopressors</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Lithium</b></p></td>
<td class="th1"><p class="tbody">N/V/D, tremor, hyperreflexia, clonus, drowsiness, seizure, ↑ QT, AV block, bradycardia</p></td>
<td class="th1"><p class="tbody">IVF (NS), maintain UOP</p>
<p class="tbody">Consider hemodialysis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Ethylene glycol</b></p></td>
<td class="th1"><p class="tbody">CNS depression, ↑ AG &amp; OG metabolic acidosis</p></td>
<td class="th1"><p class="tbody">Ethanol or fomepizole, NaHCO<sub class="calibre17">3</sub></p>
<p class="tbody">Consider hemodialysis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Methanol</b> <span class="sm">(<i class="calibre6">NEJM</i> 2018;378:270)</span></p></td>
<td class="th1"><p class="tbody">CNS depression, blindness</p>
<p class="tbody">↑ AG &amp; OG met. acidosis</p></td>
<td class="th1"><p class="tbody">Ethanol or fomepizole, NaHCO<sub class="calibre17">3</sub></p>
<p class="tbody">Consider hemodialysis</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Isopropanol</b></p></td>
<td class="th1"><p class="tbody">CNS depression, gastritis</p></td>
<td class="th1"><p class="tbody">Supportive care</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Carbon monoxide</b></p></td>
<td class="th1"><p class="tbody">HA, dizziness, nausea, ΔMS</p>
<p class="tbody">carboxyHb level, CO-oximetry</p></td>
<td class="th1"><p class="tbody">100% normobaric oxygen, hyperbaric O<sub class="calibre17">2</sub> in severe cases</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Organopho- sphate</b></p></td>
<td class="th1"><p class="tbody">Salivation, lacrimation, diaphoresis, miosis, emesis, bronchospasm, ΔMS</p></td>
<td class="th1"><p class="tbody">Endotracheal intubation for respiratory failure, atropine, pralidoxime, benzodiazepines</p></td>
</tr>
<tr class="calibre15">
<td class="th1"><p class="tbody"><b class="calibre7">Cyanide</b></p></td>
<td class="th1"><p class="tbody">Coma, seizure, metabolic acidosis, hypotension</p></td>
<td class="th1"><p class="tbody">IV Na nitrite and Na thiosulfate</p>
<p class="tbody">IV hydroxocobalamin</p></td>
</tr>
</tbody>
</table>
<p class="tfn">Call local Poison Control for assistance with management. (<i class="calibre6">Chest</i> 2011;140:1072)</p>
<h2 class="ct"><a id="h39" class="calibre8"></a><a href="part0003.html#rh44" class="calibre8">LUNG TRANSPLANT</a></h2>
<p class="h">Overview</p>
<p class="noindent1">• Indications: end stage, progressive decline despite max medical Rx, &lt;2-y life expectancy; COPD, ILD (IPF), pulmonary HTN, cystic fibrosis, alpha 1-antitrypsin</p>
<p class="noindent1">• Contraindic: age &gt;70, uncontrolled/unRx’d infxn, malig in prior 5 yrs, severe non-pulm dis., BMI ≥35 or &lt;16, active smoking, EtOH/drug depend., med nonadherence, psychosocial</p>
<p class="h">Posttransplant care</p>
<p class="noindent1">• Immunosuppression: no single best regimen. Calcineurin inhibitor (tacro &gt;cyclosporine, ↓ incidence of graft failure <span class="r1">(</span><span class="r2">JHLT</span><span class="r1"> 2021;40:S165)</span> + steroids + MMF or AZA</p>
<p class="noindent1">• Monitoring: clinic visits, serial PFTs, chest X-ray, bronchoscopy w/ transbronchial biopsy</p>
<p class="h">Complications</p>
<p class="noindent1">• Primary graft dysfunction (PGD): acute lung injury following txp; assoc w/ early mortality</p>
<p class="noindent1">• Anastomotic: vascular (stenosis, thrombosis) and airway (infection, necrosis, dehiscence, granulation tissue, tracheobronchomalacia, stenosis, fistula)</p>
<p class="noindent1">• Acute rejection: ↓ lung fxn, cough, SOB, fever; Dx w/ trans-bronch bx; Rx immunosupp</p>
<p class="noindent1">• Chronic rejection: bronchiolitis obliterans w/ obstruction; Dx w/ PFTs, trans-bronch bx; Rx limited (azithromycin, montelukast, Δ immunosuppressives)</p>
<p class="noindent1">• Infection: ↑ bacterial, fungal, viral pneumonia, systemic infections, CMV, OI</p>
<p class="noindent1">• Malignancy: 2× ↑ risk overall. 5.5× ↑ risk lung cancer. PTLD (assoc w/ EBV) common.</p>
<p class="noindent1">• Misc: GVHD, CKD, DM, CAD, CHF, stroke, encephalopathy, drug toxicity</p>


  </div>

  
  <div class="calibreToc">
    <h2><a href="../../j09u21sl.html">Table of contents
</a></h2>
    <div>
  <ul>
    <li>
      <a href="part0000.html#0-96ac16803db7461d85d0589a1c192bcf">Cover</a>
    </li>
    <li>
      <a href="part0001.html#UGI0-96ac16803db7461d85d0589a1c192bcf">Title Page</a>
    </li>
    <li>
      <a href="part0002.html#1T140-96ac16803db7461d85d0589a1c192bcf">Copyright Page</a>
    </li>
    <li>
      <a href="part0003.html#2RHM0-96ac16803db7461d85d0589a1c192bcf">Contents</a>
    </li>
    <li>
      <a href="part0004.html#3Q280-96ac16803db7461d85d0589a1c192bcf">Contributing Authors</a>
    </li>
    <li>
      <a href="part0005.html#4OIQ0-96ac16803db7461d85d0589a1c192bcf">Foreword</a>
    </li>
    <li>
      <a href="part0006.html#5N3C0-96ac16803db7461d85d0589a1c192bcf">Preface</a>
    </li>
    <li>
      <a href="part0007.html#6LJU0-96ac16803db7461d85d0589a1c192bcf">CARDIOLOGY</a>
      <ul>
        <li>
          <a href="part0007.html#h1">Electrocardiography</a>
        </li>
        <li>
          <a href="part0007.html#h2">Chest Pain</a>
        </li>
        <li>
          <a href="part0007.html#h3">Noninvasive Evaluation of CAD</a>
        </li>
        <li>
          <a href="part0007.html#h4">Coronary Angiography &amp; PCI</a>
        </li>
        <li>
          <a href="part0007.html#h5">Stable Ischemic Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h6">Acute Coronary Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h7">PA Catheter and Tailored Therapy</a>
        </li>
        <li>
          <a href="part0007.html#h8">Heart Failure</a>
        </li>
        <li>
          <a href="part0007.html#h9">Cardiomyopathies</a>
        </li>
        <li>
          <a href="part0007.html#h10">Valvular Heart Disease</a>
        </li>
        <li>
          <a href="part0007.html#h11">Pericardial Disease</a>
        </li>
        <li>
          <a href="part0007.html#h12">Hypertension</a>
        </li>
        <li>
          <a href="part0007.html#h13">Aortic Aneurysms</a>
        </li>
        <li>
          <a href="part0007.html#h14">Acute Aortic Syndromes</a>
        </li>
        <li>
          <a href="part0007.html#h15">Arrhythmias</a>
        </li>
        <li>
          <a href="part0007.html#h16">Atrial Fibrillation</a>
        </li>
        <li>
          <a href="part0007.html#h17">Syncope</a>
        </li>
        <li>
          <a href="part0007.html#h18">Cardiac Rhythm Management Devices</a>
        </li>
        <li>
          <a href="part0007.html#h19">Cardiac Risk Assessment for Noncardiac Surgery</a>
        </li>
        <li>
          <a href="part0007.html#h20">Peripheral Artery Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0008.html#7K4G0-96ac16803db7461d85d0589a1c192bcf">PULMONARY</a>
      <ul>
        <li>
          <a href="part0008.html#h21">Dyspnea</a>
        </li>
        <li>
          <a href="part0008.html#h22">Pulmonary Function Tests</a>
        </li>
        <li>
          <a href="part0008.html#h23">Asthma</a>
        </li>
        <li>
          <a href="part0008.html#h24">Anaphylaxis</a>
        </li>
        <li>
          <a href="part0008.html#h25">Chronic Obstructive Pulmonary Disease</a>
        </li>
        <li>
          <a href="part0008.html#h26">Solitary Pulmonary Nodule</a>
        </li>
        <li>
          <a href="part0008.html#h27">Hemoptysis</a>
        </li>
        <li>
          <a href="part0008.html#h28">Bronchiectasis</a>
        </li>
        <li>
          <a href="part0008.html#h29">Cystic Fibrosis</a>
        </li>
        <li>
          <a href="part0008.html#h30">Interstitial Lung Disease</a>
        </li>
        <li>
          <a href="part0008.html#h31">Pleural Effusion</a>
        </li>
        <li>
          <a href="part0008.html#h32">Venous Thromboembolism</a>
        </li>
        <li>
          <a href="part0008.html#h33">Pulmonary Hypertension</a>
        </li>
        <li>
          <a href="part0008.html#h34">Respiratory Failure</a>
        </li>
        <li>
          <a href="part0008.html#h35">Mechanical Ventilation</a>
        </li>
        <li>
          <a href="part0008.html#h36">Acute Respiratory Distress Syndrome</a>
        </li>
        <li>
          <a href="part0008.html#h37">Sepsis and Shock</a>
        </li>
        <li>
          <a href="part0008.html#h38">Toxicology</a>
        </li>
        <li>
          <a href="part0008.html#h39">Lung Transplant</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0009.html#8IL20-96ac16803db7461d85d0589a1c192bcf">GASTROENTEROLOGY</a>
      <ul>
        <li>
          <a href="part0009.html#h40">Esophageal and Gastric Disorders</a>
        </li>
        <li>
          <a href="part0009.html#h41">Gastrointestinal Bleeding</a>
        </li>
        <li>
          <a href="part0009.html#h42">Diarrhea</a>
        </li>
        <li>
          <a href="part0009.html#h43">Dysmotility &amp; Nutrition</a>
        </li>
        <li>
          <a href="part0009.html#h44">Disorders of the Colon</a>
        </li>
        <li>
          <a href="part0009.html#h45">Inflammatory Bowel Disease</a>
        </li>
        <li>
          <a href="part0009.html#h46">Intestinal Ischemia</a>
        </li>
        <li>
          <a href="part0009.html#h47">Pancreatitis</a>
        </li>
        <li>
          <a href="part0009.html#h48">Abnormal Liver Tests</a>
        </li>
        <li>
          <a href="part0009.html#h49">Hepatitis</a>
        </li>
        <li>
          <a href="part0009.html#h50">Acute Liver Failure</a>
        </li>
        <li>
          <a href="part0009.html#h51">Cirrhosis</a>
        </li>
        <li>
          <a href="part0009.html#h52">Hepatic Vascular Disease</a>
        </li>
        <li>
          <a href="part0009.html#h53">Ascites</a>
        </li>
        <li>
          <a href="part0009.html#h54">Biliary Tract Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0010.html#9H5K0-96ac16803db7461d85d0589a1c192bcf">NEPHROLOGY</a>
      <ul>
        <li>
          <a href="part0010.html#h55">Acid-Base Disturbances</a>
        </li>
        <li>
          <a href="part0010.html#h56">Sodium and Water Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h57">Potassium Homeostasis</a>
        </li>
        <li>
          <a href="part0010.html#h58">Kidney Disease</a>
        </li>
        <li>
          <a href="part0010.html#h59">Glomerular Disease</a>
        </li>
        <li>
          <a href="part0010.html#h60">Urinalysis</a>
        </li>
        <li>
          <a href="part0010.html#h61">Nephrolithiasis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0011.html#AFM60-96ac16803db7461d85d0589a1c192bcf">HEMATOLOGY-ONCOLOGY</a>
      <ul>
        <li>
          <a href="part0011.html#h62">Anemia</a>
        </li>
        <li>
          <a href="part0011.html#h63">Disorders of Hemostasis</a>
        </li>
        <li>
          <a href="part0011.html#h64">Platelet Disorders</a>
        </li>
        <li>
          <a href="part0011.html#h65">Coagulopathies</a>
        </li>
        <li>
          <a href="part0011.html#h66">Hypercoagulable States</a>
        </li>
        <li>
          <a href="part0011.html#h67">Disorders of Leukocytes</a>
        </li>
        <li>
          <a href="part0011.html#h68">Transfusion Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h69">Myelodysplastic Syndromes</a>
        </li>
        <li>
          <a href="part0011.html#h70">Myeloproliferative Neoplasms</a>
        </li>
        <li>
          <a href="part0011.html#h71">Leukemia</a>
        </li>
        <li>
          <a href="part0011.html#h72">Lymphoma and CLL</a>
        </li>
        <li>
          <a href="part0011.html#h73">Plasma Cell Dyscrasias</a>
        </li>
        <li>
          <a href="part0011.html#h74">Hematopoietic Stem Cell Transplantation</a>
        </li>
        <li>
          <a href="part0011.html#h75">Lung Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h76">Breast Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h77">Prostate Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h78">Colorectal Cancer</a>
        </li>
        <li>
          <a href="part0011.html#h79">Pancreatic Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h80">Other Solid Tumors</a>
        </li>
        <li>
          <a href="part0011.html#h81">Immunotherapy &amp; Cellular Therapy</a>
        </li>
        <li>
          <a href="part0011.html#h82">Oncologic Emergencies</a>
        </li>
        <li>
          <a href="part0011.html#h83">Chemo Side Effects</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0012.html#BE6O0-96ac16803db7461d85d0589a1c192bcf">INFECTIOUS DISEASES</a>
      <ul>
        <li>
          <a href="part0012.html#h84">Pneumonia</a>
        </li>
        <li>
          <a href="part0012.html#h85">Fungal Infections</a>
        </li>
        <li>
          <a href="part0012.html#h86">Infxns in Immunosuppressed Hosts</a>
        </li>
        <li>
          <a href="part0012.html#h87">Urinary Tract Infections</a>
        </li>
        <li>
          <a href="part0012.html#h88">Sexually Transmitted Infections</a>
        </li>
        <li>
          <a href="part0012.html#h89">Skin and Soft Tissue Infections</a>
        </li>
        <li>
          <a href="part0012.html#h90">Infections of the Nervous System</a>
        </li>
        <li>
          <a href="part0012.html#h91">Bacteremia &amp; Endocarditis</a>
        </li>
        <li>
          <a href="part0012.html#h92">Tuberculosis</a>
        </li>
        <li>
          <a href="part0012.html#h93">HIV/AIDS</a>
        </li>
        <li>
          <a href="part0012.html#h94">Tick-Borne Diseases</a>
        </li>
        <li>
          <a href="part0012.html#h95">Fever Syndromes</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0013.html#CCNA0-96ac16803db7461d85d0589a1c192bcf">ENDOCRINOLOGY</a>
      <ul>
        <li>
          <a href="part0013.html#h96">Pituitary Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h97">Thyroid Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h98">Adrenal Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h99">Calcium Disorders</a>
        </li>
        <li>
          <a href="part0013.html#h100">Diabetes Mellitus</a>
        </li>
        <li>
          <a href="part0013.html#h101">Lipid Disorders</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0014.html#DB7S0-96ac16803db7461d85d0589a1c192bcf">RHEUMATOLOGY</a>
      <ul>
        <li>
          <a href="part0014.html#h102">Approach to Rheumatic Disease</a>
        </li>
        <li>
          <a href="part0014.html#h103">Rheumatoid Arthritis</a>
        </li>
        <li>
          <a href="part0014.html#h104">Adult-Onset Still’s Disease &amp; Relapsing Polychondritis</a>
        </li>
        <li>
          <a href="part0014.html#h105">Crystal Deposition Arthritides</a>
        </li>
        <li>
          <a href="part0014.html#h106">Seronegative Spondyloarthritis</a>
        </li>
        <li>
          <a href="part0014.html#h107">Infectious Arthritis &amp; Bursitis</a>
        </li>
        <li>
          <a href="part0014.html#h108">Connective Tissue Diseases</a>
        </li>
        <li>
          <a href="part0014.html#h109">Systemic Lupus Erythematosus</a>
        </li>
        <li>
          <a href="part0014.html#h110">IgG4-Related Disease</a>
        </li>
        <li>
          <a href="part0014.html#h111">Vasculitis</a>
        </li>
        <li>
          <a href="part0014.html#h112">Autoinflammatory Syndromes</a>
        </li>
        <li>
          <a href="part0014.html#h113">Amyloidosis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0015.html#E9OE0-96ac16803db7461d85d0589a1c192bcf">NEUROLOGY</a>
      <ul>
        <li>
          <a href="part0015.html#h114">Change in Mental Status</a>
        </li>
        <li>
          <a href="part0015.html#h115">Seizures</a>
        </li>
        <li>
          <a href="part0015.html#h116">Alcohol Withdrawal</a>
        </li>
        <li>
          <a href="part0015.html#h117">Dizziness</a>
        </li>
        <li>
          <a href="part0015.html#h118">Stroke</a>
        </li>
        <li>
          <a href="part0015.html#h119">Weakness &amp; Neuromuscular Dysfunction</a>
        </li>
        <li>
          <a href="part0015.html#h120">Headache</a>
        </li>
        <li>
          <a href="part0015.html#h121">Back and Spinal Cord Disease</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0016.html#F8900-96ac16803db7461d85d0589a1c192bcf">CONSULTS</a>
      <ul>
        <li>
          <a href="part0016.html#h122">Surgical Issues</a>
        </li>
        <li>
          <a href="part0016.html#h123">Ob/Gyn Issues</a>
        </li>
        <li>
          <a href="part0016.html#h124">Ophthalmic Issues</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0017.html#G6PI0-96ac16803db7461d85d0589a1c192bcf">APPENDIX</a>
      <ul>
        <li>
          <a href="part0017.html#h125">ICU Medications</a>
        </li>
        <li>
          <a href="part0017.html#h126">Antibiotics</a>
        </li>
        <li>
          <a href="part0017.html#h127">Formulae and Quick Reference</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0018.html#H5A40-96ac16803db7461d85d0589a1c192bcf">ABBREVIATIONS</a>
    </li>
    <li>
      <a href="part0019.html#I3QM0-96ac16803db7461d85d0589a1c192bcf">INDEX</a>
    </li>
    <li>
      <a href="part0020.html#J2B80-96ac16803db7461d85d0589a1c192bcf">PHOTO INSERTS</a>
      <ul>
        <li>
          <a href="part0020.html#h128">Radiology</a>
        </li>
        <li>
          <a href="part0020.html#h129">Echocardiography</a>
        </li>
        <li>
          <a href="part0020.html#h130">Coronary Angiography</a>
        </li>
        <li>
          <a href="part0020.html#h131">Peripheral Blood Smears</a>
        </li>
        <li>
          <a href="part0020.html#h132">Leukemias</a>
        </li>
        <li>
          <a href="part0020.html#h133">Urinalysis</a>
        </li>
      </ul>
    </li>
    <li>
      <a href="part0021.html#K0RQ0-96ac16803db7461d85d0589a1c192bcf">ACLS</a>
    </li>
  </ul>
</div>


  </div>
  

  <div class="calibreEbNav">
    
      <a href="part0007.html" class="calibreAPrev">previous page
</a>
    

    <a href="../../j09u21sl.html" class="calibreAHome">start
</a>

    
      <a href="part0009.html" class="calibreANext">next page
</a>
    
  </div>

</div>

</body>
</html>
